The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

Jérémy Manry; Paul Bastard; Adrian Gervais; Tom Le Voyer; Jérémie Rosain; Quentin Philippot; Eleftherios Michailidis; Hans-Heinrich Hoffmann; Shohei Eto; Marina Garcia-Prat; Lucy Bizien; Alba Parra-Martínez; Rui Yang; Liis Haljasmägi; Mélanie Migaud; Karita Särekannu; Julia Maslovskaja; Nicolas de Prost; Yacine Tandjaoui-Lambiotte; Charles-Edouard Luyt; Blanca Amador-Borrero; Alexandre Gaudet; Julien Poissy; Pascal Morel; Pascale Richard; Fabrice Cognasse; Jesús Troya; Sophie Trouillet-Assant; Alexandre Belot; Kahina Saker; Pierre Garçon; Jacques G Rivière; Jean-Christophe Lagier; Stéphanie Gentile; Lindsey B Rosen; Elana Shaw; Tomohiro Morio; Junko Tanaka; David Dalmau; Pierre-Louis Tharaux; Damien Sene; Alain Stepanian; Bruno Mégarbane; Vasiliki Triantafyllia; Arnaud Fekkar; James R Heath; José Luis Franco; Juan-Manuel Anaya; Jordi Solé-Violán; Luisa Imberti; Andrea Biondi; Paolo Bonfanti; Riccardo Castagnoli; Ottavia M Delmonte; Yu Zhang; Andrew L Snow; Steven M Holland; Catherine M Biggs; Marcela Moncada-Vélez; Andrés Augusto Arias; Lazaro Lorenzo; Soraya Boucherit; Dany Anglicheau; Anna M Planas; Filomeen Haerynck; Sotirija Duvlis; Tayfun Ozcelik; Sevgi Keles; Ahmed A Bousfiha; Jalila El Bakkouri; Carolina Ramirez-Santana; Stéphane Paul; Qiang Pan-Hammarström; Lennart Hammarström; Annabelle Dupont; Alina Kurolap; Christine N Metz; Alessandro Aiuti; Giorgio Casari; Vito Lampasona; Fabio Ciceri; Lucila A Barreiros; Elena Dominguez-Garrido; Mateus Vidigal; Mayana Zatz; Diederik van de Beek; Sabina Sahanic; Ivan Tancevski; Yurii Stepanovskyy; Oksana Boyarchuk; Yoko Nukui; Miyuki Tsumura; Loreto Vidaur; Stuart G Tangye; Sonia Burrel; Darragh Duffy; Lluis Quintana-Murci; Adam Klocperk; Nelli Y Kann; Anna Shcherbina

doi:10.1073/pnas.2200413119

. 2022 May 16;119(21):e2200413119. doi: 10.1073/pnas.2200413119

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

Jérémy Manry ^a,^b,¹, Paul Bastard ^a,^b,^c,², Adrian Gervais ^a,^b,², Tom Le Voyer ^a,^b,², Jérémie Rosain ^a,^b,², Quentin Philippot ^a,^b,², Eleftherios Michailidis ^d,³, Hans-Heinrich Hoffmann ^d,³, Shohei Eto ^e,³, Marina Garcia-Prat ^f,³, Lucy Bizien ^a,^b,³, Alba Parra-Martínez ^f,³, Rui Yang ^c,³, Liis Haljasmägi ^g,³, Mélanie Migaud ^a,^b,³, Karita Särekannu ^g,³, Julia Maslovskaja ^g,³, Nicolas de Prost ^h,ⁱ, Yacine Tandjaoui-Lambiotte ^j,⁴, Charles-Edouard Luyt ^k,^l, Blanca Amador-Borrero ^m, Alexandre Gaudet ^n,^o, Julien Poissy ^n,^o, Pascal Morel ^p,^q, Pascale Richard ^p, Fabrice Cognasse ^r,^s, Jesús Troya ^t, Sophie Trouillet-Assant ^u,^v,^w, Alexandre Belot ^u,^v,^x,^y, Kahina Saker ^u,^v, Pierre Garçon ^z, Jacques G Rivière ^f, Jean-Christophe Lagier ^aa, Stéphanie Gentile ^bb,^cc, Lindsey B Rosen ^dd, Elana Shaw ^dd, Tomohiro Morio ^ee, Junko Tanaka ^ff, David Dalmau ^gg,^hh, Pierre-Louis Tharaux ⁱⁱ, Damien Sene ^m, Alain Stepanian ^jj,^kk, Bruno Mégarbane ^ll, Vasiliki Triantafyllia ^mm, Arnaud Fekkar ^a,ⁿⁿ, James R Heath ^oo, José Luis Franco ^pp, Juan-Manuel Anaya ^qq,⁵, Jordi Solé-Violán ^rr,^ss,^tt, Luisa Imberti ^uu, Andrea Biondi ^vv, Paolo Bonfanti ^ww, Riccardo Castagnoli ^dd,^xx, Ottavia M Delmonte ^dd, Yu Zhang ^dd,^yy, Andrew L Snow ^zz, Steven M Holland ^dd, Catherine M Biggs ^aaa, Marcela Moncada-Vélez ^c, Andrés Augusto Arias ^c,^bbb,^ccc, Lazaro Lorenzo ^a,^b, Soraya Boucherit ^a,^b, Dany Anglicheau ^ddd,^eee, Anna M Planas ^fff,^ggg, Filomeen Haerynck ^hhh, Sotirija Duvlis ^iii,^jjj, Tayfun Ozcelik ^kkk, Sevgi Keles ^lll, Ahmed A Bousfiha ^mmm,ⁿⁿⁿ, Jalila El Bakkouri ^mmm,ⁿⁿⁿ, Carolina Ramirez-Santana ^ooo, Stéphane Paul ^ppp, Qiang Pan-Hammarström ^qqq, Lennart Hammarström ^qqq, Annabelle Dupont ^rrr, Alina Kurolap ^sss, Christine N Metz ^ttt, Alessandro Aiuti ^uuu, Giorgio Casari ^uuu, Vito Lampasona ^vvv, Fabio Ciceri ^www, Lucila A Barreiros ^xxx, Elena Dominguez-Garrido ^yyy, Mateus Vidigal ^zzz, Mayana Zatz ^zzz, Diederik van de Beek ^aaaa, Sabina Sahanic ^bbbb, Ivan Tancevski ^bbbb, Yurii Stepanovskyy ^cccc, Oksana Boyarchuk ^dddd, Yoko Nukui ^eeee, Miyuki Tsumura ^e, Loreto Vidaur ^ffff,^gggg, Stuart G Tangye ^hhhh,ⁱⁱⁱⁱ, Sonia Burrel ^jjjj, Darragh Duffy ^kkkk, Lluis Quintana-Murci ^llll,^mmmm, Adam Klocperk ⁿⁿⁿⁿ, Nelli Y Kann ^oooo, Anna Shcherbina ^oooo, Yu-Lung Lau ^pppp, Daniel Leung ^pppp, Matthieu Coulongeat ^qqqq, Julien Marlet ^rrrr,^ssss, Rutger Koning ^aaaa, Luis Felipe Reyes ^tttt,^uuuu, Angélique Chauvineau-Grenier ^vvvv, Fabienne Venet ^wwww,^xxxx,^yyyy, Guillaume Monneret ^wwww,^yyyy, Michel C Nussenzweig ^zzzz,^aaaaa, Romain Arrestier ^h,ⁱ, Idris Boudhabhay ^ddd,^eee, Hagit Baris-Feldman ^sss,^bbbbb, David Hagin ^bbbbb,^ccccc, Joost Wauters ^ddddd, Isabelle Meyts ^eeeee,^fffff, Adam H Dyer ^ggggg,^hhhhh, Sean P Kennelly ^ggggg,^hhhhh, Nollaig M Bourke ^hhhhh, Rabih Halwani ^iiiii,^jjjjj, Fatemeh Saheb Sharif-Askari ⁱⁱⁱⁱⁱ, Karim Dorgham ^kkkkk, Jérôme Sallette ^lllll, Souad Mehlal Sedkaoui ^lllll, Suzan AlKhater ^mmmmm,ⁿⁿⁿⁿⁿ, Raúl Rigo-Bonnin ^ooooo, Francisco Morandeira ^ppppp, Lucie Roussel ^qqqqq,^rrrrr, Donald C Vinh ^qqqqq,^rrrrr, Christian Erikstrup ^sssss, Antonio Condino-Neto ^xxx, Carolina Prando ^ttttt, Anastasiia Bondarenko ^cccc, András N Spaan ^c,^uuuuu, Laurent Gilardin ^vvvvv,^wwwww, Jacques Fellay ^xxxxx,^yyyyy,^zzzzz, Stanislas Lyonnet ^aaaaaa, Kaya Bilguvar ^bbbbbb,^cccccc,^dddddd,^eeeeee, Richard P Lifton ^bbbbbb,^cccccc,^ffffff, Shrikant Mane ^cccccc; HGID Lab^ef,^eg,^eh,⁶; COVID Clinicians^ef,^eg,^eh,⁶; COVID-STORM Clinicians^ef,^eg,^eh,⁶; NIAID Immune Response to COVID Group^ef,^eg,^eh,⁶; NH-COVAIR Study Group^ef,^eg,^eh,⁶; Danish CHGE^ef,^eg,^eh,⁶; Danish Blood Donor Study^ef,^eg,^eh,⁶; St. James's Hospital, SARS CoV2 Interest Group^ef,^eg,^eh,⁶; French COVID Cohort Study Group^ef,^eg,^eh,⁶; Imagine COVID-Group^ef,^eg,^eh,⁶; The Milieu Intérieur Consortium^ef,^eg,^eh,⁶; CoV-Contact Cohort^ef,^eg,^eh,⁶; Amsterdam UMC Covid-19 Biobank Investigators^ef,^eg,^eh,⁶; COVID Human Genetic Effort^ef,^eg,^eh,⁶; CP-COVID-19 Group^ef,^eg,^eh,⁶; CONSTANCES cohort^ef,^eg,^eh,⁶; 3C-Dijon Study^ef,^eg,^eh,⁶; Cerba Health-Care^ef,^eg,^eh,⁶; Etablissement Français du Sang Study group^ef,^eg,^eh,⁶, Mark S Anderson ^gggggg, Bertrand Boisson ^a,^b,^c, Vivien Béziat ^a,^b,^c, Shen-Ying Zhang ^a,^b,^c, Evangelos Andreakos ^mm,⁷, Olivier Hermine ^b,^hhhhhh,⁷, Aurora Pujol ^iiiiii,^jjjjjj,^kkkkkk,⁷, Pärt Peterson ^g,⁷, Trine H Mogensen ^llllll,^mmmmmm,⁷, Lee Rowen ^oo,⁷, James Mond ^nnnnnn,^7,⁸, Stéphanie Debette ^oooooo,^pppppp,⁷, Xavier de Lamballerie ^qqqqqq,⁷, Charles Burdet ^rrrrrr,^ssssss,^tttttt,⁷, Lila Bouadma ^ssssss,^uuuuuu,⁷, Marie Zins ^vvvvvv,⁷, Pere Soler-Palacin ^f,⁷, Roger Colobran ^wwwwww,⁷, Guy Gorochov ^kkkkk,^xxxxxx,⁷, Xavier Solanich ^yyyyyy,⁷, Sophie Susen ^rrr,⁷, Javier Martinez-Picado ^zzzzzz,^aaaaaaa,^bbbbbbb,^ccccccc,^ddddddd,⁷, Didier Raoult ^aa,⁷, Marc Vasse ^eeeeeee,⁷, Peter K Gregersen ^ttt,⁷, Lorenzo Piemonti ^vvv,⁷, Carlos Rodríguez-Gallego ^tt,^fffffff,⁷, Luigi D Notarangelo ^dd,⁹, Helen C Su ^dd,^ggggggg,⁹, Kai Kisand ^g,⁹, Satoshi Okada ^e,⁹, Anne Puel ^a,^b,^c,⁹, Emmanuelle Jouanguy ^a,^b,^c,⁹, Charles M Rice ^d,⁹, Pierre Tiberghien ^p,^q,⁹, Qian Zhang ^a,^b,^c,⁹, Jean-Laurent Casanova ^a,^b,^c,^aaaaa,^10,¹, Laurent Abel ^a,^b,^c,¹⁰, Aurélie Cobat ^a,^b,^c,^10,¹

^aLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, 75015 Paris, France;

^bImagine Institute, University of Paris, 75015 Paris, France;

^cSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065;

^dLaboratory of Virology and Infectious Disease, Rockefeller University, New York, NY 10065;

^eDepartment of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan;

^fPediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain;

^gInstitute of Biomedicine and Translational Medicine, University of Tartu, 50090 Tartu, Estonia;

^hService de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris, 94010 Créteil, France;

ⁱGroupe de Recherche Clinique Cardiovascular and Respiratory Manifestations of Acute Lung Injury and Sepsis (CARMAS), Faculté de santé de Créteil, Université Paris Est Créteil, 94010 Créteil Cedex, France;

^jHypoxia and Lung, INSERM U1272, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, 93022 Bobigny, France;

^kSorbonne Université, Hôpital Pitié Salpêtrière, Médecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France;

^lINSERM, UMRS 1166-iCAN, Institute of Cardiometabolism and Nutrition, 75013 Paris, France;

^mInternal Medicine Department, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, 75010 Paris, France;

ⁿINSERM U1019–CNRS UMR9017, Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, 59000 Lille, France;

^oCentre Hospitalier Universitaire, de Lille, Pôle de Réanimation, Hôpital Roger Salengro Lille, 59000 Lille, France;

^pEtablissement Français du Sang, 93218 La Plaine Saint-Denis, France;

^qInteractions Hôte-Greffon-Tumeur et Ingénierie Cellulaire et Génique (RIGHT), INSERM, Etablissement Français du Sang, Université de Franche-Comté, 25000 Besançon, France;

^rSanté Ingéniérie Biologie St-Etienne (SAINBIOSE), INSERM U1059, University of Lyon, Université Jean Monnet Saint-Etienne, 42000 Saint-Étienne, France;

^sEtablissement Français du Sang, Auvergne-Rhône-Alpes, 42000 Saint-Étienne, France;

^tDepartment of Internal Medicine, Infanta Leonor University Hospital, 28031 Madrid, Spain;

^uHospices Civils de Lyon, 69002 Lyon, France;

^vInternational Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, Ecole Nationale Supérieure, Université Claude Bernard Lyon 1 (UCBL), 69365 Lyon, France;

^wJoint Research Unit, Hospices Civils de Lyon-BioMérieux, Hospices Civils de Lyon, Lyon Sud Hospital, 69495 Pierre-Bénite, France;

^xNational Referee Centre for Rheumatic, and Autoimmune and Systemic Diseases in Children, 69000 Lyon, France;

^yImmunopathology Federation Lyon Immunopathology Federation (LIFE), Hospices Civils de Lyon, 69002 Lyon, France;

^zIntensive Care Unit, Grand Hôpital de l’Est Francilien Site de Marne-La-Vallée, 77600 Jossigny, France;

^aaMicrobes, Evolution, Phylogénie et Infection (MEPHI), Institut Hospitalo-Universitaire Méditerranée Infection, Institut de Recherche pour le Développement, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, 13005 Marseille, France;

^bbService d’Evaluation Médicale, Hôpitaux Universitaires de Marseille Assistance Publique Hôpitaux de Marseille, 13005 Marseille, France;

^ccAix-Marseille University, School of Medicine, EA 3279, Centre d'Études et de Recherche sur les Services de Santé et la Qualité de vie (CEReSS)–Health Service Research and Quality of Life Center, 13385 Marseille, France;

^ddLaboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892;

^eeDepartment of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan;

^ffDepartment of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan;

^ggHospital Universitari MútuaTerrassa, Universitat de Barcelona, 08193 Barcelona, Spain;

^hhFundació Docència i Recerca Mutua Terrassa, 08221 Terrassa, Spain;

ⁱⁱParis Cardiovascular Research Center (PARCC), INSERM, Université de Paris, 75015 Paris, France;

^jjService d’Hématologie Biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Université de Paris, 75010 Paris, France;

^kkEA3518, Institut Universitaire d’Hématologie-Hôpital Saint Louis, Université de Paris, 75010 Paris, France;

^llRéanimation Médicale et Toxicologique, Hôpital Lariboisière Assistance Publique-Hôpitaux de Paris, Université de Paris, INSERM, UMRS-1144, 75010 Paris, France;

^mmLaboratory of Immunobiology, Center for Clinical, Experimental Surgery, and Translational Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece;

ⁿⁿService de Parasitologie-Mycologie, Groupe Hospitalier Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75013 Paris, France;

^ooInstitute for Systems Biology, Seattle, WA 98109;

^ppPrimary Immunodeficiencies Group, Department of Microbiology and Parasitology, School of Medicine, University of Antioquia UdeA, 050010 Medellín, Colombia;

^qqCenter for Autoimmune Disease Research, School of Medicine and Health Sciences, Universidad del Rosario, 110111 Bogotá, Colombia;

^rrIntensive Care Medicine, University Hospital of Gran Canaria Dr. Negrín, Canarian Health System, 35010 Las Palmas de Gran Canaria, Spain;

^ssCentro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias, Instituto de Salud Carlos III, 28029 Madrid, Spain;

^ttDepartment of Clinical Sciences, Universidad Fernando Pessoa Canarias, 35450 Las Palmas de Gran Canaria, Spain;

^uuCHemato-oncology Research Laboratory of Associazione italiana contro le leucemie-linfomi e mieloma, Diagnostic Departement, Azienda Socio Sanitaria Territoriale, Spedali Civili di Brescia, 25123 Brescia, Italy;

^vvPediatric Department and Centro Tettamanti-European Reference Network PaedCan, EuroBloodNet, European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN), University of Milano Bicocca, Fondazione Monza Brianza Bambino Mamma (MBBM), Ospedale San Gerardo, 20900 Monza, Italy;

^wwDepartment of Infectious Diseases, San Gerardo Hospital, University of Milano Bicocca, 20900 Monza, Italy;

^xxPediatric Clinic, Fondazione Istituto di Ricovero e Cura a carattere scientifico (IRCCS) Policlinico San Matteo, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy;

^yyNational Institute of Allergy and Infectious Diseases (NIAID) Clinical Genomics Program, NIH, Bethesda, MD 20892;

^zzDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814;

^aaaDepartment of Pediatrics, British Columbia Children’s Hospital, University of British Columbia, Vancouver, BC V6H 0B3, Canada;

^bbbPrimary Immunodeficiencies Group, University of Antioquia UdeA, 050010 Medellin, Colombia;

^cccSchool of Microbiology, University of Antioquia UdeA, 050010 Medellin, Colombia;

^dddDepartment of Nephrology and Transplantation, Necker University Hospital, Assistance Publique-Hôpitaux de Paris, 75743 Paris, France;

^eeeInstitut Necker Enfants Malades, INSERM U1151–CNRS UMR 8253, Université de Paris, 75015 Paris, France;

^fffInstitute for Biomedical Research, Spanish National Research Council, 08036 Barcelona, Spain;

^gggInstitut d’Investigacions Biomèdiques August Pi i Sunyer, 08036 Barcelona, Spain;

^hhhDepartment of Paediatric Immunology and Pulmonology, Center for Primary Immunodeficiency Ghent, Jeffrey Modell Diagnosis and Research Center, Ghent University Hospital, 9000 Ghent, Belgium;

ⁱⁱⁱFaculty of Medical Sciences, University “Goce Delchev,” Štip 2000, Republic of North Macedonia;

^jjjInstitute of Public Health of the Republic of North Macedonia, Skopje 1000, Republic of North Macedonia;

^kkkDepartment of Molecular Biology and Genetics, Bilkent University, 06800 Ankara, Turkey;

^lllMeram Faculty of Medicine, Necmettin Erbakan University, 42080 Konya, Turkey;

^mmmClinical Immunology Unit, Department of Pediatric Infectious Disease, Centre Hospitalier-Universitaire Ibn Roucshd, 20360 Casablanca, Morocco;

ⁿⁿⁿLaboratoire d’Immunologie Clinique, Inflammation et Allergie (LICIA), Faculty of Medicine and Pharmacy, Hassan II University, 20250 Casablanca, Morocco;

^oooCenter for Autoimmune Disease Research, School of Medicine and Health Sciences, Universidad del Rosario, 111211 Bogotá, Colombia;

^pppDepartment of Immunology, CIC1408, Groupe sur l’Immunité des Muqueuses et des Agents Pathogènes (GIMAP) Centre International de Recherche en Infectiologie, INSERM U1111, University Hospital of Saint-Étienne, 42000 Saint-Étienne, France;

^qqqDepartment of Biosciences and Nutrition, Karolinska Institutet, 171 77 Stockholm, Sweden;

^rrrUniversity of Lille, INSERM, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, U1011-European Genomic Institute for Diabetes (EGID), F-59000 Lille, France;

^sssThe Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center, 6423906 Tel Aviv, Israel;

^tttFeinstein Institutes for Medical Research, Northwell Health, Manhasset, NY 11030;

^uuuVita-Salute San Raffaele University, and Clinical Genomics, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, 20132 Milan, Italy;

^vvvDiabetes Research Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, 20132 Milan, Italy;

^wwwHematology and Bone Marrow Transplantation Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele University Vita-Salute San Raffaele, 20132 Milano, Italy;

^xxxDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, 05508-060 São Paulo, Brazil;

^yyyFundación Rioja Salud, Centro de Investigación Biomédica de La Rioja, 26006 Logroño, Spain;

^zzzUniversity of São Paulo, 05508-060 São Paulo, Brazil;

^aaaaDepartment of Neurology, Amsterdam UMC, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands;

^bbbbDepartment of Internal Medicine II, Medical University of Innsbruck, 6020 Innsbruck, Austria;

^ccccShupyk National Healthcare University of Ukraine, 04112 Kyiv, Ukraine;

^ddddDepartment of Children’s Diseases and Pediatric Surgery, I. Horbachevsky Ternopil National Medical University, 46022 Ternopil, Ukraine;

^eeeeDepartment of Infection Control and Prevention, Medical Hospital, Tokyo Medical and Dental University, Tokyo 113-8655, Japan;

^ffffIntensive Care Medicine, Donostia University Hospital, Biodonostia Institute of Donostia, 20014 San Sebastián, Spain;

^ggggCentro de Investigación Biomédica en Red (CIBER) de Enfermedades Respiratorias, Instituto de Salud Carlos III, 28029 Madrid, Spain;

^hhhhGarvan Institute of Medical Research, Sydney, NWS 2010, Australia;

ⁱⁱⁱⁱSt Vincent’s Clinical School, Faculty of Medicine and Health, University of New South Wales, Sydney, NWS 2010, Australia;

^jjjjSorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Service de Virologie, 75013 Paris, France;

^kkkkTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, 75015 Paris, France;

^llllHuman Evolutionary Genetics Unit, Institut Pasteur, CNRS UMR 2000, 75015 Paris, France;

^mmmmDepartment of Human Genomics and Evolution, Collège de France, 75231 Paris, France;

ⁿⁿⁿⁿDepartment of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, 150 06 Prague, Czech Republic;

^ooooDepartment of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia 117997;

^ppppDepartment of Paediatrics and Adolescent Medicine, University of Hong Kong, Hong Kong 999077, China;

^qqqqDivision of Geriatric Medicine, Tours University Medical Center, 37044 Tours, France;

^rrrrINSERM U1259, Morphogenèse et Antigénicité du VIH et des Virus des Hépatites (MAVIVH), Université de Tours, 37044 Tours, France;

^ssssService de Bactériologie, Virologie et Hygiène Hospitalière, Centre Hospitalier Universitaire de Tours, 37044 Tours, France;

^ttttDepartment of Microbiology, Universidad de La Sabana, 250001 Chía, Colombia;

^uuuuDepartment of Critical Care Medicine, Clínica Universidad de La Sabana, 250001 Chía, Colombia;

^vvvvService de Biologie Médicale, Centre Hospitalier Intercommunal Robert Ballanger, 93600 Aulnay-sous-Bois, France;

^wwwwLaboratoire d’Immunologie, Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437 Lyon, France;

^xxxxCentre International de Recherche en Infectiologie, INSERM U1111, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, 69007 Lyon, France;

^yyyyEA 7426, Pathophysiology of Injury-Induced Immunosuppression, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, BioMérieux, Hôpital Edouard Herriot, 69437 Lyon, France;

^zzzzLaboratory of Molecular Immunology, Rockefeller University, New York, NY 10065;

^aaaaaHHMI, Rockefeller University, New York, NY 10065;

^bbbbbSackler Faculty of Medicine, Tel Aviv University, 6997801 Tel Aviv, Israel;

^cccccAllergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center, 6423906 Tel Aviv, Israel;

^dddddMedical Intensive Care Unit, University Hospitals Leuven, 3000 Leuven, Belgium;

^eeeeeLaboratory of Inborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, Katholieke Universiteit Leuven, 3000 Leuven, Belgium;

^fffffDepartment of Pediatrics, Jeffrey Modell Diagnostic and Research Network Center, University Hospitals Leuven, 3000 Leuven, Belgium;

^gggggDepartment of Age-Related Healthcare, Tallaght University Hospital, Dublin D24 NR0A, Ireland;

^hhhhhDepartment of Medical Gerontology, School of Medicine, Trinity College Dublin, Dublin D08 W9RT, Ireland;

ⁱⁱⁱⁱⁱSharjah Institute for Medical Research, College of Medicine, University of Sharjah, 27272 Sharjah, United Arab Emirates;

^jjjjjImmunology Research Lab, College of Medicine, King Saud University, 11362 Riyadh, Saudi Arabia;

^kkkkkSorbonne Université, INSERM, Centre d’Immunologie et des Maladies Infectieuses, 75013 Paris, France;

^lllllCerba HealthCare, 92130 Issy-les-Moulineaux, France;

^mmmmmDepartment of Pediatrics, King Fahad Hospital of the University, Al Khobar 34445, Saudi Arabia;

ⁿⁿⁿⁿⁿCollege of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia;

^oooooDepartment of Clinical Laboratory, Hospital Universitari de Bellvitge, The Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain;

^pppppDepartment of Immunology, Hospital Universitari de Bellvitge, The Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain;

^qqqqqDepartment of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montréal, QC H4A 3J1, Canada;

^rrrrrInfectious Disease Susceptibility Program, Research Institute of the McGill University Health Centre, Montréal, QC H4A 3J1, Canada;

^sssssDepartment of Clinical Immunology, Aarhus University Hospital, 8000 Aarhus, Denmark;

^tttttFaculdades Pequeno Príncipe, Instituto de Pesquisa Pelé Pequeno Príncipe, 80250-200 Curitiba, Brazil;

^uuuuuDepartment of Medical Microbiology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands;

^vvvvvService de Médecine Interne, Hôpital Universitaire Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93140 Bondy, France;

^wwwwwINSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris, France;

^xxxxxSchool of Life Sciences, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland;

^yyyyyPrecision Medicine Unit, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland;

^zzzzzSwiss Institute of Bioinformatics, 1015 Lausanne, Switzerland;

^aaaaaaImagine Institute, Université de Paris, INSERM, UMR 1163, 75015 Paris, France;

^bbbbbbYale Center for Genome Analysis, Yale School of Medicine, New Haven, CT 06511;

^ccccccDepartment of Genetics, Yale University School of Medicine, New Haven, CT 06520;

^ddddddDepartment of Neurosurgery, Yale University School of Medicine, New Haven, CT 06510;

^eeeeeeDepartment of Medical Genetics, Acibadem University School of Medicine, 34750 Istanbul, Turkey;

^ef^ffffffLaboratory of Human Genetics and Genomics, Rockefeller University, New York, NY 10065;

^eg^ggggggDiabetes Center, University of California, San Francisco, CA 94143;

^eh^hhhhhhDepartment of Hematology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France;

ⁱⁱⁱⁱⁱⁱNeurometabolic Diseases Laboratory, The Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain;

^jjjjjjCentre for Biomedical Research on Rare Diseases (CIBERER) U759, Instituto de Salud Carlos III, 28029 Madrid, Spain;

^kkkkkkCatalan Institution of Research and Advanced Studies (ICREA), 08010 Barcelona, Spain;

^llllllDepartment of Infectious Diseases, Aarhus University Hospital, 8000 Aarhus, Denmark;

^mmmmmmDepartment of Biomedicine, Aarhus University, 8000 Aarhus, Denmark;

ⁿⁿⁿⁿⁿⁿADMA Biologics Inc., Ramsey, NJ 07446;

^ooooooUniversity of Bordeaux, INSERM, Bordeaux Population Health Center, UMR1219, F-33000 Bordeaux, France;

^ppppppDepartment of Neurology, Institute of Neurodegenerative Diseases, Bordeaux University Hospital, F-33000 Bordeaux, France;

^qqqqqqInstitut Hospitalo-Universitaire Méditerranée Infection, Unité des Virus Émergents, Aix-Marseille University, Institut pour la Recherche et le Développment (IRD) 190, INSERM 1207, 13005 Marseille, France;

^rrrrrrEpidémiologie clinique du Centre d’Investigation Clinique (CIC-EP), INSERM CIC 1425, Hôpital Bichat, 75018 Paris, France;

^ssssssUniversité de Paris, Infection Antimicrobials Modelling Evolution (IAME), UMR 1137, INSERM, 75870 Paris, France;

^ttttttDépartement Epidémiologie, Biostatistiques et Recherche Clinique, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, 75018 Paris, France;

^uuuuuuService de Réanimation Médicale et des Maladies Infectieuses, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Nord Université de Paris, F-75018 Paris, France;

^vvvvvvCohorte Constances Groupe Hospitalier Universitaire centre, Assistance Publique-Hôpitaux de Paris, Université de Paris, 94800 Villejuif, France;

^wwwwwwImmunology Division, Genetics Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain;

^xxxxxxDépartement d’Immunologie, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpétrière, 75015 Paris, France;

^yyyyyyDepartment of Internal Medicine, Hospital Universitari de Bellvitge, The Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain;

^zzzzzzIrsiCaixa AIDS Research Institute, 08916 Badalona, Spain;

^aaaaaaaInstitute for Health Science Research Germans Trias i Pujol (IGTP), 08916 Badalona, Spain;

^bbbbbbbDepartment of Infectious Diseases and Immunity, University of Vic-Central University of Catalonia, 08500 Vic, Spain;

^cccccccCatalan Institution of Research and Advanced Studies (ICREA), 08010 Barcelona, Spain;

^dddddddConsorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain;

^eeeeeeeService de Biologie Clinique and UMR-S 1176, Hôpital Foch, 92150 Suresnes, France;

^fffffffDepartment of Immunology, University Hospital of Gran Canaria Dr. Negrin, Canarian Health System, 35010 Las Palmas de Gran Canaria, Spain;

^gggggggDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104;

To whom correspondence may be addressed. Email: jeremy.manry@inserm.fr, casanova@rockefeller.edu, or aurelie.cobat@inserm.fr.

Contributed by Jean-Laurent Casanova; received January 10, 2022; accepted March 17, 2022; reviewed by Mary Carrington, Antoine Flahault, and Amalio Telenti

Author contributions: J. Manry, L.A., and A.C. designed research; J. Manry, P. Bastard, A. Gervais, T.L.V., J.R., Q.P., E.M., H.-H.H., S.E., M.G.-P., L. Bizien, A.P.-M., R.Y., L. Haljasmägi, M.M., K. Särekannu, J. Maslovskaja, C.-E.L., S.T.-A., A. Belot, K. Saker, L.B.R., E.S., A. Fekkar, O.M.D., Y.Z., S.M.H., M.M.-V., A.A.A., B.B., V.B., S.-Y.Z., L.D.N., H.C.S., K.K., S.O., A. Puel, E.J., C.M.R., Q.Z., and A.C. performed research; P. Bastard, J.R., N.d.P., Y.T.-L., B.A.-B., A. Gaudet, J.P., P.M., P.R., F. Cognasse, J. Troya, S.T.-A., A. Belot, K. Saker, P.G., J.G.R., J.-C.L., S.G., T.M., J. Tanaka, D. Dalmau, P.-L.T., D.S., A. Stepanian, B.M., V.T., J.R.H., J.L.F., J.-M.A., J.S.-V., L.I., A. Biondi, P. Bonfanti, R. Castagnoli, A.L.S., C.M.B., L.L., S. Boucherit, D.A., A.M.P., F.H., S. Duvlis, T.O., S.K., A.A.B., J.E.B., C.R.-S., S.P., Q.P.-H., L. Hammarström, A.D., A. Kurolap, C.N.M., A.A., G.C., V.L., F. Ciceri, L.A.B., E.D.-G., M. Vidigal, M. Zatz, D.v.d.B., S. Sahanic, I.T., Y.S., O.B., Y.N., M.T., L.V., S.G.T., S. Burrel, D. Duffy, L.Q.-M., A. Klocperk, N.Y.K., A. Shcherbina, Y.-L.L., D.L., M. Coulongeat, J. Marlet, R.K., L.F.R., A.C.-G., F.V., G.M., M.C.N., R.A., I.B., H.B.-F., D.H., J.W., I.M., A.H.D., S.P.K., N.M.B., R.H., F.S.S.-A., K.D., J.S., S.M.S., S.A., R.R.-B., F.M., L. Roussel, D.C.V., C.E., A.C.-N., C.P., A. Bondarenko, A.N.S., L.G., J.F., S.L., K.B., R.P.L., S.M., M.S.A., E.A., O.H., A. Pujol, P.P., T.H.M., L. Rowen, J. Mond, S. Debette, X.d.L., C.B., L. Bouadma, M. Zins, P.S.-P., R. Colobran, G.G., X.S., S. Susen, J.M.-P., D.R., M. Vasse, P.K.G., L.P., C.R.-G., L.D.N., H.C.S., P.T., Q.Z., and J.-L.C. contributed new reagents/analytic tools; J. Manry, L.A., and A.C. analyzed data; and J. Manry, J.-L.C., L.A., and A.C. wrote the paper.

²P. Bastard, A. Gervais, T.L.V., J.R., and Q.P. contributed equally to this work.

³E.M., H.-H.H., S.E., M.G.-P., L. Bizien, A.P.-M., R.Y., L. Haljasmägi, M.M., K. Särekannu, and J. Maslovskaja contributed equally to this work.

⁴Present address: Hypoxia and Lung INSERM U1272, Pneumologie & Infectiologie INSERM UMR 1137, Infection Antimicrobials Modelling Evolution, Centre Hospitalier Saint-Denis, 93200 Saint-Denis, France.

⁵Present address: National Academy of Medicine of Colombia, 110231 Bogota, Colombia.

⁶Lists of members of consortia are available in SI Appendix.

⁷E.A., O.H., A. Pujol, P.P., T.H.M., L. Rowen, J. Mond, S. Debette, X.d.L., C.B., L. Bouadma, M. Zins, P.S.-P., R. Colobran, G.G., X.S., S. Susen, J.M.-P., D.R., M. Vasse, P.K.G., L.P., and C.R.-G. contributed equally to this work.

⁸Present address: Gain Therapeutics, 6900 Lugano, Switzerland.

⁹L.D.N., H.C.S., K.K., S.O., A. Puel, E.J., C.M.R., P.T., Q.Z. contributed equally to this work.

¹⁰J.-L.C., L.A., and A.C. contributed equally to this work.

PMCID: PMC9173764 PMID: 35576468

Significance

There is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It is important to estimate their quantitative impact on COVID-19 mortality upon SARS-CoV-2 infection, by age and sex, as both the prevalence of these autoantibodies and the risk of COVID-19 death increase with age and are higher in men. Using an unvaccinated sample of 1,261 deceased patients and 34,159 individuals from the general population, we found that autoantibodies against type I IFNs strongly increased the SARS-CoV-2 infection fatality rate at all ages, in both men and women. Autoantibodies against type I IFNs are strong and common predictors of life-threatening COVID-19. Testing for these autoantibodies should be considered in the general population.

Keywords: COVID-19, type I IFNs, autoantibodies, relative risk, infection fatality rate

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IFN-ω, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals <70 y and ≥70 y old, respectively, whereas, for autoantibodies neutralizing both molecules, the RRDs were 188.3 (44.8 to 774.4) and 7.2 (5.0 to 10.3), respectively. In contrast, IFRs increased with age, ranging from 0.17% (0.12 to 0.31) for individuals <40 y old to 26.7% (20.3 to 35.2) for those ≥80 y old for autoantibodies neutralizing IFN-α2 or IFN-ω, and from 0.84% (0.31 to 8.28) to 40.5% (27.82 to 61.20) for autoantibodies neutralizing both. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, especially when neutralizing both IFN-α2 and IFN-ω. Remarkably, IFRs increase with age, whereas RRDs decrease with age. Autoimmunity to type I IFNs is a strong and common predictor of COVID-19 death.

There have already been more than 250 million severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and at least 5 million deaths from COVID-19 worldwide. Interindividual clinical variability in the course of infection with SARS-CoV-2 is immense, ranging from silent infection in about 40% of cases to acute respiratory distress syndrome in ∼3% of cases (1–5). Death occurs in ∼1% of cases (6). Age is the strongest epidemiological predictor of COVID-19 death, with the risk of death doubling every 5 y of age from childhood onward (6, 7). Men are also at greater risk of death than women (5, 8). Based on previously identified inborn errors of type I interferon (IFN) immunity (9), the COVID Human Genetic Effort (10) has shown that type I IFN immunity is essential for protective immunity to respiratory infection with SARS-CoV-2 (11–14). We have reported that inborn errors of Toll-like receptor 3 (TLR3)-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in a small subset of patients (14). Biochemically deleterious mutations of eight genes were found in 23 patients with critical COVID-19 (3.5% of 659 patients), including 18 patients under 60 y old. Remarkably, four unrelated patients, aged 25 y to 50 y, had autosomal recessive (AR) deficiencies of IFNAR1 or IRF7, including three homozygotes (two for IFNAR1 and one for IRF7) and one compound heterozygote (for IRF7). Three other patients with AR IFNAR1 or TBK1 deficiency were independently reported (15–17). The penetrance of those defects is unknown, but it is probably higher for AR than for autosomal dominant disorders. We then reported that X-linked recessive TLR7 deficiency accounted for 1.8% of cases of life-threatening COVID-19 in men under 60 y old (13, 18). The penetrance of this disorder is apparently high but incomplete, especially in children. Deficiencies of IFNAR1 and IRF7 blunt type I IFN immunity across cell types, whereas defects of the TLR3 and TLR7 pathway preferentially affect respiratory epithelial cells and plasmacytoid dendritic cells, respectively (13, 19).

We have also reported the presence of autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, with plasma diluted 1/10) of IFN-α2 and/or IFN-ω in about 10% of patients with critical COVID-19 pneumonia but not in individuals with asymptomatic or mild infection (12). This finding has already been replicated in 14 other cohorts (20–35). We then detected auto-Abs neutralizing lower, more physiological concentrations (100 pg/mL, with plasma diluted 1/10) of IFN-α2 and/or IFN-ω in 13.6% of patients with life-threatening COVID-19, and 18% of deceased patients (11). The proportion of male patients was greater in patients with auto-Abs than in patients without auto-Abs (11, 12). In addition, 1.3% of patients with critical COVID-19 had auto-Abs neutralizing IFN-β (10 ng/mL, with plasma diluted 1/10), most without auto-Abs neutralizing IFN-α2 or IFN-ω. The prevalence of auto-Abs neutralizing IFN-α2 and/or IFN-ω in the general population increased with age, from 0.18% for 10 ng/mL and 1% for 100 pg/mL in individuals between 18 y and 69 y old to 3.4% for 10 ng/mL and 6.3% for 100 pg/mL for individuals over 80 y old (11). The prevalence of auto-Abs against IFN-β did not increase with age. The crude odds ratios (ORs) for critical COVID-19 as opposed to asymptomatic or mild infection in auto-Ab carriers relative to noncarriers ranged from 3 to 67, depending on the type I IFNs recognized and the concentrations neutralized (11). At least 12 lines of evidence strongly suggest that auto-Abs against type I IFNs are strong determinants of COVID-19 death (Table 1). The specific impact of these auto-Abs on COVID-19 mortality according to age and sex remains unknown and is of major interest (52, 53), as both the prevalence of these auto-Abs and the risk of death increase with age and are higher in men. Here, using data reported by Bastard et al. (11), we estimated the relative risk of COVID-19 death (RRD) for type I IFN auto-Ab carriers relative to noncarriers and the corresponding SARS-CoV-2 infection fatality rate (IFR), by sex and age category.

Table 1.

Lines of evidence suggesting that auto-Abs against type I IFNs are strong determinants of the risk of life-threatening COVID-19

Evidence	Examples	References
Auto-Abs against type I IFNs are present before SARS-CoV-2 infection	In patients for whom a sample collected before the COVID-19 pandemic was available, the auto-Abs were found to preexist infection.	(36)
	These auto-Abs are found in the uninfected general population, and their prevalence increases after the age of 65 y.	(11)
Auto-Abs are associated with COVID-19 severity	Patients with inborn errors underlying these auto-Abs from infancy onward (e.g., APS-1) have a very high risk of developing critical COVID-19 pneumonia.	(36)
	The population of patients with critical disease includes a higher proportion of individuals producing these auto-Abs than the population of patients with silent or mild infection (ORs depending on the nature, number, and concentrations of type I IFN neutralized).	(11)
	The results concerning the proportions of critical cases with auto-Abs against type I IFNs have already been replicated in >15 different cities (Americas, Europe, Asia).	(20, 23–35)
Auto-Abs against type I IFNs neutralize host antiviral activity	These auto-Abs neutralize the antiviral activity of type I IFNs against SARS-CoV-2 in vitro.	(12)
	These auto-Abs are found in vivo in the blood of SARS-CoV-2-infected patients, where they neutralize type I IFN.	(37)
	These auto-Abs are found in vivo in the respiratory tract of patients, where they neutralize type I IFN.	(38–40)
	A key virulence factor of SARS-CoV-2 in vitro is its capacity to impair type I IFN immunity.	(41)
	Animals with type I IFN deficiency develop critical disease, including animals treated with mAbs that neutralize type I IFNs.	(42)
Auto-Abs against cytokines are clinical phenocopies of the corresponding inborn errors	Patients with auto-Abs against type I IFNs are phenocopies of IFNAR1^−/−, IFNAR2^−/−, and IRF7^−/− patients with critical COVID-19 pneumonia.	(14)
	Patients with auto-Abs against IL-6, IL-17, GM-CSF, and type II IFN are phenocopies of the corresponding inborn errors and underlie staphylococcal disease, mucocutaneous candidiasis, nocardiosis, and mycobacterial diseases, respectively.	(43–51)

Open in a new tab

Results

Patients and Controls.

We estimated the RRD of individuals carrying auto-Abs neutralizing type I IFNs relative to noncarriers by Firth’s logistic regression, using large samples of 1,261 patients who died from COVID-19 and 34,159 individuals from the general population from whom samples were collected before the pandemic. In this study design, in which controls are sampled from the baseline population regardless of disease status, the ORs obtained by logistic regression approximate the relative risks (RRs) in the absence of the assumption of rare disease (54) (SI Appendix, Supplementary Materials and Methods). We confirmed that this statement remains valid in our study design, using Firth’s logistic regression by a simulation study (SI Appendix, Supplementary Materials and Methods and Fig. S1). For auto-Abs neutralizing low concentrations (100 pg/mL) of IFN-α2 and/or IFN-ω, we used 1,121 patients who died from COVID-19, and 10,778 individuals from the general population (Table 2). Assessments of auto-Abs neutralizing high concentrations (10 ng/mL) of IFN-α2 and/or IFN-ω were available for 1,094 deceased patients, and 34,159 individuals from the general population (Table 2). We also had assessments of auto-Abs neutralizing 10 ng/mL of IFN-β for a subsample of 636 deceased patients, and 9,126 individuals from the general population (Table 2). RRDs were estimated by means of Firth’s bias-corrected logistic regression, considering death as a binary outcome and adjusting for sex and age in six classes (20 y to 39 y, 40 y to 49 y, 50 y to 59 y, 60 y to 69 y, 70 y to 79 y, and ≥80 y). For assessment of the effect of age and sex on RRD, we added interaction terms between auto-Abs and age, and auto-Abs and sex terms to the logistic model (Materials and Methods and SI Appendix, Supplementary Materials and Methods).

Table 2.

Characteristics of the general population cohort and of the cohort of patients who died from COVID-19

	Neutralization 100 pg/mL		Neutralization 10 ng/mL
Characteristics	General population (n = 10,778)	Deceased patients (n = 1,121)	General population (n = 34,159)	Deceased patients (n = 1,094)
Male – no. (percent)	5,429 (50.4)^*	821 (73.2)	17,859 (52.3)	805 (73.5)
Mean age ± SD^* – years	62.3 ± 17.2	70.7 ± 13.0	52.7 ± 18.2	70.6 ± 13.1
Age distribution – no. (percent)
20 y to 39 y	1,251 (11.6)	17 (1.5)	9,102 (26.6)	15 (1.4)
40 y to 49 y	1,459 (13.5)	43 (3.8)	5,403 (15.8)	47 (4.3)
50 y to 59 y	1,736 (16.1)	144 (12.8)	6,414 (18.9)	152 (13.9)
60 y to 69 y	2,475 (23.0)	307 (27.4)	6,881 (20.1)	289 (26.4)
70 y to 79 y	1,790 (16.6)	307 (27.4)	3,721 (10.9)	296 (27.1)
≥80 y	2,067 (19.2)	303 (27.0)	2,638 (7.7)	295 (27.0)
Auto-Ab – no. of carriers (percent)
IFN-α2 and IFN-ω	65 (0.6)	102 (9.1)	45 (0.1)	75 (6.8)
IFN-α2 or IFN-ω	246 (2.3)	203 (18.1)	181 (0.5)	130 (11.9)
IFN-α2	151 (1.4)	140 (12.5)	117 (0.3)	118 (10.8)
IFN-ω	160 (1.5)	165 (14.7)	109 (0.3)	87 (8.0)
IFN-β^†	NA	NA	24 (0.3)	6 (0.9)

Open in a new tab

NA, not available.

*Age is given in years and corresponds to age at the time of recruitment for members of the general population cohort (controls) and age at death for COVID-19 patients.

^†IFN-β neutralization experiments were performed only for a concentration of 10 ng/mL, on 9,126 individuals (49.5% male, mean age 60.6 y) from the general population and 636 COVID-19 patients (71.1% male, mean age 72.9 y).

RRD for Carriers of Auto-Abs Neutralizing Low Concentrations of Type I IFNs.

We first estimated the RRD for individuals carrying auto-Abs neutralizing low concentrations of IFN-α2 or IFN-ω. As expected, increasing age and maleness were highly significantly associated with greater risk of COVID-19 death (P values ≤ 10⁻¹⁶; SI Appendix, Table S1). Different age classes were used to test the interaction with the presence of auto-Abs, and the best fit was obtained with a two-age class model (20 y to 69 y and ≥70 y; SI Appendix, Table S2) with a significant effect of the interaction term between auto-Abs and age (P value = 4 × 10⁻⁶). The RRD associated with auto-Abs did not vary significantly with sex (P value = 0.81). These interaction results are fully consistent with the distribution of RRD according to age (Fig. 1A) and sex (Fig. 1B), with a clear decrease in RRD after the age of 70 y, and no sex effect. Overall, the RRD for individuals carrying auto-Abs neutralizing IFN-α2 or IFN-ω decreased from 17.0 (95% CI: 11.7 to 24.7) before the age of 70 y to 5.8 (4.5 to 7.4) for individuals ≥70 y old (Fig. 2A and SI Appendix, Table S3). We then applied the same strategy to other combinations of auto-Abs neutralizing low concentrations of IFN, and observed similar age effects on RRDs (SI Appendix, Table S1). The presence of auto-Abs neutralizing both IFN-α2 and IFN-ω was associated with the highest RRD, estimated at 188.3 (45.8 to 774.4) for individuals under the age of 70 y and 7.2 (5.0 to 10.3) for those over 70 y old (Fig. 2A and SI Appendix, Table S3). We also estimated the population attributable fraction (PAF), to assess the proportion of COVID-19 deaths attributable to auto-Abs (SI Appendix, Supplemental Materials and Methods). Given the high RRD estimated for all combinations of auto-Abs neutralizing low concentrations of type I IFNs, the PAF was very close to the prevalence of these auto-Abs in deceased patients (SI Appendix, Table S3).

Fig. 1. — RRDs for individuals with auto-Abs neutralizing low concentrations of IFN-α2 or IFN-ω relative to individuals without such auto-Abs, by age and sex. RRDs are displayed on a logarithmic scale (A) for six age classes and (B) for male and female subjects under and over the age of 70 y. Vertical bars represent the 95% CI.

Fig. 2. — RRDs for individuals with auto-Abs neutralizing different combinations of type I IFNs relative to individuals without such auto-Abs, by age. RRDs are displayed on a logarithmic scale for individuals under and over 70 y of age with (A) auto-Abs neutralizing low concentrations of IFN-α2 and IFN-ω, IFN-α2 or IFN-ω, IFN-α2, and IFN-ω and (B) auto-Abs neutralizing high concentrations of IFN-α2 and IFN-ω, IFN-α2 or IFN-ω, IFN-α2, IFN-ω, and IFN-β, relative to individuals without such combinations of auto-Abs. Vertical bars represent the 95% CI.

RRD for Carriers of Auto-Abs Neutralizing High Concentrations of Type I IFNs.

We then estimated the RRD for the presence versus the absence of auto-Abs neutralizing high concentrations (10 ng/mL) of type I IFN. The effect of age on RRD was similar to that observed with auto-Abs neutralizing low concentrations of type I IFN, with the use of two age classes providing the best fit (SI Appendix, Tables S2 and S4), and a decrease of RRD with age (Fig. 2B and SI Appendix, Table S5). The RRD for carriers of IFN-α2 or IFN-ω auto-Abs decreased from 62.4 (38.4 to 101.3) before the age of 70 y to 6.8 (5.1 to 9.2) after the age of 70 y, whereas carriers of auto-Abs against both IFN-α2 and IFN-ω had the highest RRD, estimated at 156.5 (57.8 to 423.4) and 12.9 (8.4 to 19.9) for subjects <70 y and ≥70 y old, respectively (Fig. 2B and SI Appendix, Table S5). Individuals carrying auto-Abs neutralizing high concentrations of IFN-α2 and/or IFN-ω had a significantly higher RRD than individuals carrying only auto-Abs neutralizing low concentrations (SI Appendix, Supplemental Materials and Methods). This finding, consistent with the higher proportion of auto-Abs neutralizing high concentrations in deceased patients than in the general population (SI Appendix, Fig S2), suggests a more deleterious impact of auto-Abs neutralizing high concentrations of IFN-α2 and/or IFN-ω on COVID-19 outcomes. Finally, auto-Abs neutralizing high doses of IFN-β had the lowest RRD before 70 y (7.0 [2.2 to 22.4]), with no significant age-dependent association (P value = 0.37). The PAF for auto-Abs neutralizing high concentrations of type I IFNs was also close to the prevalence of these auto-Abs in deceased patients (SI Appendix, Table S5).

IFR in Individuals Carrying Auto-Abs Neutralizing Low Concentrations of Type I IFNs.

We then estimated the IFR in SARS-CoV-2–infected individuals carrying auto-Abs neutralizing low concentrations of type I IFNs (IFR_AAB). According to Bayes’ theorem, IFR_AAB can be expressed as a function of the age-dependent prevalence of auto-Abs in deceased patients and in the general population together with the reported age-specific IFR (6) (SI Appendix). For all combinations of auto-Abs, the IFR_AAB was much higher than the overall IFR. Fig. 3 illustrates this much higher IFR for carriers of auto-Abs neutralizing low concentrations of IFN-α2 or IFN-ω; it exceeded 1% and 10% for subjects over the ages of 40 y and 60 y, respectively. Considering other combinations of auto-Abs, the highest IFR_AAB was observed for carriers of auto-Abs neutralizing both IFN-α2 and IFN-ω, reaching 40.5% (27.8 to 61.2) in individuals over 80 y old (Fig. 4A and SI Appendix, Table S6). IFR_AAB values were similar for all other combinations of auto-Abs. For example, the IFR_AAB for individuals carrying auto-Abs neutralizing either IFN-α2 or IFN-ω ranged from 0.17% (0.12 to 0.31) in individuals under 40 y old to 26.7% (20.3 to 35.2) in individuals over 80 y old. An exception was noted for the IFR_AAB of carriers of anti-IFN-α2 auto-Abs, which was 1.8 to 2.6 times higher than that for carriers of auto-Abs neutralizing IFN-α2 or IFN-ω in subjects under 60 y old. The IFR_AAB was also generally higher in male subjects than in female subjects, particularly in individuals carrying auto-Abs neutralizing both IFN-α2 and IFN-ω (∼2.7 times higher) (SI Appendix, Fig. S3).

Fig. 3. — SARS-CoV-2 IFRs by age. IFRs are provided for the general population for both sexes (gray) and for males only (blue), from the data of O’Driscoll et al. (6); IFR_AAB (green) are shown for individuals carrying auto-Abs neutralizing low concentrations of IFN-α2 or IFN-ω. Auto-Abs against type I IFNs are associated with high RRDs and strongly increase the IFR, to a much greater extent than being male, and, by inference, than other common classical risk factors providing ORs of death similar to that for being male (around two), such as certain comorbid conditions, or the most significant common genetic variant on chromosome 3 (5).

Fig. 4. — SARS-CoV-2 IFRs for carriers of various combinations of neutralizing auto-Abs, by age. IFR_AAB values (percent) are displayed, on a logarithmic scale, by age, for individuals with (A) auto-Abs neutralizing low concentrations of IFN-α2 and IFN-ω, IFN-α2 or IFN-ω, IFN-α2, and IFN-ω and (B) auto-Abs neutralizing high concentrations of IFN-α2 and IFN-ω, IFN-α2 or IFN-ω, IFN-α2, IFN-ω, and IFN-β. Vertical bars represent the 95% CI. Horizontal black lines represent the IFR provided by O’Driscoll et al. (6).

IFR in Individuals Carrying Auto-Abs Neutralizing High Concentrations of Type I IFNs.

The age-, sex-, and type I IFN–dependent patterns of IFR_AAB observed for carriers of auto-Abs neutralizing high concentrations of IFN-α2 and/or IFN-ω were similar to those previously obtained for carriers of auto-Abs neutralizing low concentrations of these molecules, but with higher values. For example, IFR_AAB ranged from 3.1% (1.3 to 20.8) before 40 y of age to 68.7% (42.5 to 95.8) in those over 80 y old for carriers of auto-Abs neutralizing high concentrations of both IFN-α2 and IFN-ω (Fig. 4B and SI Appendix, Table S7). IFR_AAB values were ∼5 times higher in male than in female subjects, across all age groups and auto-Abs combinations (SI Appendix, Fig. S4). For carriers of auto-Abs neutralizing IFN-β (tested only at high concentration), IFR_AAB was lower (by a factor of 6 to 71) than for individuals under the age of 80 y with auto-Abs neutralizing IFN-α2 and/or IFN-ω. It ranged from 0.04% (0.01 to 0.16) for individuals under the age of 40 y to 2.2% (0.2 to 9.3) for the 70- to 79-y age group. In the oldest age class, IFR_AAB was 31.0% (2.4 to 88.1), similar to that for carriers of auto-Abs against IFN-α2 or IFN-ω, albeit with a large confidence interval.

Discussion

In this study, we took advantage of our previous data (11) to estimate RRDs associated with auto-Abs across age groups. We also confirmed, by a simulation study, that, in our design, ORs obtained by Firth’s logistic regression were reliable estimates of RR. In addition, we used IFR values previously reported for the general population (6) to estimate IFR_AAB under the plausible hypothesis that the prevalence of auto-Abs in the general population is a reliable estimation of the prevalence of auto-Abs in infected individuals (SI Appendix, Supplemental Materials and Methods). We report high RRDs for carriers of auto-Abs neutralizing type I IFNs, ranging from 2.6 for auto-Abs neutralizing IFN-β (high concentration) in subjects over 70 y old to >150 for auto-Abs neutralizing both IFN-α2 and IFN-ω in subjects under 70 y old. For all types of auto-Abs, RRDs were 3 to 26 times higher in subjects under 70 y old than in older individuals. This is consistent with the increasing prevalence of auto-Abs in the general population with age (∼1% under 70 y of age and >4% over 70 y of age), whereas the proportion of deceased patients with these auto-Abs is stable across age categories (∼15 to 20%). The lower RRD observed in the elderly may be partly explained epidemiologically, by the larger contribution of other mortality risk factors, such as comorbid conditions, which become more frequent with increasing age. At the cellular level, aging is associated with immunosenescence, which may contribute to a defective innate and adaptive response to SARS-CoV-2 infection, thereby conferring a predisposition to severe COVID-19 (55). At the molecular level, global type I IFN immunity in the blood (plasmacytoid dendritic cells) and respiratory tract (respiratory epithelial cells) has been shown to decline with age (56–59). These epidemiological, cellular, and molecular factors probably overlap. Thus, despite their increasing prevalence with age, auto-Abs against type I IFNs make a decreasing contribution to the risk of COVID-19 death with age, due to the progressive development of additional age-dependent risk factors, including other mechanisms of type I IFN deficiency. However, for the very same reasons, IFR_AAB increases dramatically with age in patients with auto-Abs, reaching 68.7% for carriers of auto-Abs neutralizing high concentrations of both IFN-α2 and IFN-ω.

RRD and IFR_AAB varied considerably with the IFNs recognized and the concentrations neutralized by auto-Abs. For combinations involving auto-Abs against IFN-α2 and/or IFN-ω, the neutralization of low concentrations was associated with a lower RRD and a lower IFR_AAB than the neutralization of high concentrations, suggesting that residual type I IFN activity may be beneficial in at least some patients. Blood IFN-α concentrations during acute asymptomatic or paucisymptomatic SARS-CoV-2 infection typically range from 1 pg/mL to 100 pg/mL (11). In addition, the presence of auto-Abs neutralizing both IFN-α2 and IFN-ω was associated with the highest RRD and IFR_AAB values. Interestingly, IFN-α2 and IFN-ω are encoded by two genes, IFNA2 and IFNW1, that have been shown to have evolved under strong selective constraints (60), consistent with their neutralization being harmful to the host. In addition, patients with auto-Abs against IFN-α2 have been shown to neutralize all 13 IFN-α subtypes (11, 12), rendering any potential IFN-α redundancy inoperative (11, 12). Accordingly, the IFR_AAB values for carriers of auto-Abs against IFN-α2 were higher than those for carriers of auto-Abs against IFN-ω in subjects under 60 y of age. In older age groups, this difference tended to disappear, consistent with the lower impact of auto-Abs in the elderly, as discussed above. Finally, auto-Abs neutralizing IFN-β were less common, and associated with lower RRD and IFR_AAB values (by about one order of magnitude) than auto-Abs against IFN-α2 and/or IFN-ω, in all age groups except the over-80s. This less deleterious effect of auto-Abs neutralizing IFN-β is consistent with a mouse study showing that the blockade of IFN-β alone does not alter the early dissemination of lymphocytic choriomeningitis virus (61). Overall, auto-Abs against type I IFNs are associated with very high RRD and IFR values, and the magnitude of this effect appears to be much larger than that of other known common risk factors apart from age, such as maleness (Fig. 4), comorbidities, or the most significant common genetic variant on chromosome 3, all of which have been associated with life-threatening COVID-19 with ORs of about two (5).

Despite the lower prevalence of these auto-Abs in younger than in older individuals, the much higher IFR_AAB observed in individuals with these auto-Abs suggests that the testing of infected individuals in all age groups is warranted. Particular attention should be paid to patients, especially children, with known autoimmune or genetic conditions associated with the production of auto-Abs against type I IFNs. Early treatments could be provided (62), including monoclonal antibodies (63), new antiviral drugs, and/or IFN-β in the absence of auto-Abs against IFN-β (64, 65). Rescue treatment by plasma exchange is a therapeutic option in patients who already have pneumonia (36). A screening of uninfected elderly people could be considered, given that these auto-Abs are found in 4% of individuals over 70 y old. Carriers of auto-Abs should be vaccinated against SARS-CoV-2 as a priority, and should benefit from a booster, whatever their age, and, ideally, from a monitoring of their antibody response to the vaccine. They should not receive live-attenuated vaccines, including the yellow fever vaccine (YFV-17D) and anti-SARS-CoV-2 vaccines based on the YFV-17D backbone (66). In cases of SARS-CoV-2 infection, vaccinated patients should be closely monitored. As SARS-CoV-2 vaccination coverage increases and mortality due to COVID-19 decreases over time, it will be important to reevaluate the risk of fatal COVID-19 in vaccinated individuals with and without auto-Abs. It is currently unclear whether these auto-Abs impair antibody responses to vaccines, and whether a vaccine-triggered antibody response can overcome type I IFN deficiency in response to large or even medium-sized viral inocula. Finally, further investigations are required to determine the contribution of these auto-Abs to other severe viral diseases, and to elucidate the mechanisms underlying their development, which may be age dependent. In the meantime, auto-Abs against type I IFNs should be considered as a leading common predictor of life-threatening COVID-19, after age, as their detection appears to have a much greater predictive value for death, and, by inference, hospitalization and critical COVID-19, than sex, comorbidities, and common genetic variants (Fig. 3).

Materials and Methods

Study Design.

We enrolled 1,261 patients aged 20 y to 99 y old who died from COVID-19 pneumonia before SARS-CoV-2 vaccines became available, and 34,159 controls from the adult general population from whom samples were collected before the COVID-19 pandemic, as previously described (11). The experiments involving human subjects were performed in accordance with institutional, local, and national ethical guidelines. Approval was obtained from the French Ethics Committee “Comité de Protection des Personnes,” the French National Agency for Medicine and Health Product Safety, and the “Institut National de la Santé et de la Recherche Médicale,” in France (protocol C10-13, ID-RCB number 2010-A00634-35), and the Rockefeller University Institutional Review Board in New York (protocol JCA-0700). Participants were consented prior to sampling and collection of clinical data. Auto-Ab determinations were performed as described by Bastard et al. (11, 66), and were classified as neutralizing high concentrations (10 ng/mL) of IFN-α2, IFN-ω, or IFN-β, or low concentrations (100 pg/mL) of IFN-α2 or IFN-ω (SI Appendix, Supplemental Materials and Methods).

RRDs and IFRs for Carriers of Neutralizing Autoantibodies.

We estimated the RRD in individuals carrying auto-Abs neutralizing type I IFNs relative to noncarriers, using large samples of patients who died from COVID-19 and of individuals from the general population. For each combination of auto-Abs, a Firth’s bias-corrected logistic regression model, including auto-Ab status, sex, and age, was fitted (SI Appendix, Table S1). For assessments of the effect of age and sex on the RRD due to auto-Abs, we added interaction terms between auto-Abs and sex, and auto-Abs and age (SI Appendix, Supplemental Materials and Methods). A similar Firth’s logistic regression model was used in the subsample of carriers of auto-Abs, to assess the deleteriousness of auto-Abs neutralizing high concentrations relative to those neutralizing low concentrations of type I IFNs (SI Appendix, Supplemental Materials and Methods). From the RRD, we calculated the PAF to assess the proportion of COVID-19 deaths attributable to auto-Abs. The PAF can be estimated as follows: P(auto-Abs/death) * (1 − 1/RRD) (67), where P(auto-Abs/death) is the prevalence of auto-Abs in deceased patients.

Our goal was also to estimate the fatality rate upon infection with SARS-CoV-2 (IFR) in unvaccinated subjects carrying auto-Abs against type I IFNs across age groups and sexes. To this end, we used the fatality rate upon infection with SARS-CoV-2 in the general unvaccinated population provided by O’Driscoll et al. (6). We estimated the IFR for carriers of neutralizing auto-Abs infected with SARS-CoV-2 (IFR_AAB) following Bayes’ theorem, and using the age-dependent prevalence of auto-Abs in deceased patients and in the general population together with the reported age-specific IFR (6) as detailed in SI Appendix, Supplemental Materials and Methods.

Supplementary Material

Supplementary File

pnas.2200413119.sapp.pdf^{(1,008.8KB, pdf)}

Acknowledgments

We thank the patients and their families for placing their trust in us. We thank the members of both branches of the Laboratory of Human Genetics of Infectious Diseases. We thank Y. Nemirovskaya, M. Woollett, D. Liu, S. Boucherit, C. Rivalain, M. Chrabieh, and L. Lorenzo for administrative assistance. We also thank the staff of the Imagine facilities: C. Bureau, L. Colonna, S. Paillet, N. Ghouas, and M. Sy. We are also grateful to the legal team and technology transfer staff of the Imagine Institute: M. Pilorges, R. Marlanges, E. Rubino, W. Loewen, D. Beudin, and N. Wuylens. We thank all the staff of the Imagine Institute, Necker Hospital, and Necker sorting center for help. We thank S. Nagashima (Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan). The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute; The Rockefeller University; the St. Giles Foundation; the NIH (Grants R01AI088364 and R01AI163029); the National Center for Advancing Translational Sciences; NIH Clinical and Translational Science Awards program (Grant UL1 TR001866); a Fast Grant from Emergent Ventures; Mercatus Center at George Mason University; the Yale Center for Mendelian Genomics and the Genome Sequencing Program Coordinating Center funded by the National Human Genome Research Institute (Grants UM1HG006504 and U24HG008956); the Yale High Performance Computing Center (Grant S10OD018521); the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPB Foundation; the French National Research Agency (ANR) under the “Investments for the Future” program (Grant ANR-10-IAHU-01); the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (Grant ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM) (Grant EQU201903007798); the French Agency for Research on AIDS and Viral hepatitis (ANRS) Nord-Sud (Grant ANRS-COV05); the ANR GENVIR (Grant ANR-20-CE93-003), AABIFNCOV (Grant ANR-20-CO11-0001), CNSVIRGEN (Grant ANR-19-CE15-0009-01), and GenMIS-C (Grant ANR-21-COVR-0039) projects; the Square Foundation; Grandir–Fonds de solidarité pour l’Enfance; the Fondation du Souffle; the SCOR Corporate Foundation for Science; The French Ministry of Higher Education, Research, and Innovation (Grant MESRI-COVID-19); Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM; and the University Paris Cité. P. Bastard was supported by the FRM (Award EA20170638020). P. Bastard., J.R., and T.L.V. were supported by the MD-PhD program of the Imagine Institute (with the support of Fondation Bettencourt Schueller). Work at the Neurometabolic Disease lab received funding from Centre for Biomedical Research on Rare Diseases (CIBERER) (Grant ACCI20-767) and the European Union's Horizon 2020 research and innovation program under grant agreement 824110 (EASI Genomics). Work in the Laboratory of Virology and Infectious Disease was supported by the NIH (Grants P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1), a George Mason University Fast Grant, and the G. Harold and Leila Y. Mathers Charitable Foundation. The Infanta Leonor University Hospital supported the research of the Department of Internal Medicine and Allergology. The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (Grant RECOVER WP 6). This work was also partly supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases and the National Institute of Dental and Craniofacial Research, NIH (Grants ZIA AI001270 to L.D.N. and 1ZIAAI001265 to H.C.S.). This program is supported by the Agence Nationale de la Recherche (Grant ANR-10-LABX-69-01). K.K.’s group was supported by the Estonian Research Council, through Grants PRG117 and PRG377. R.H. was supported by an Al Jalila Foundation Seed Grant (Grant AJF202019), Dubai, United Arab Emirates, and a COVID-19 research grant (Grant CoV19-0307) from the University of Sharjah, United Arab Emirates. S.G.T. is supported by Investigator and Program Grants awarded by the National Health and Medical Research Council of Australia and a University of New South Wales COVID Rapid Response Initiative Grant. L.I. reports funding from Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”). This research was partially supported by the Instituto de Salud Carlos III (Grant COV20/0968). J.R.H. reports funding from Biomedical Advanced Research and Development Authority (Grant HHSO10201600031C). S.O. reports funding from Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development (Grant JP20fk0108531). G.G. was supported by the ANR Flash COVID-19 program and SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University iCOVID programs. The 3C Study was conducted under a partnership agreement between INSERM, Victor Segalen Bordeaux 2 University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also supported by the Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Direction générale de la Santé, Mutuelle Générale de l’Education Nationale, Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Program “Cohortes et collections de données biologiques.” S. Debette was supported by the University of Bordeaux Initiative of Excellence. P.K.G. reports funding from the National Cancer Institute, NIH, under Contract 75N91019D00024, Task Order 75N91021F00001. J.W. is supported by a Research Foundation - Flanders (FWO) Fundamental Clinical Mandate (Grant 1833317N). Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. Work at Vall d’Hebron was also partly supported by research funding from Instituto de Salud Carlos III Grant PI17/00660 cofinanced by the European Regional Development Fund (ERDF/FEDER). C.R.-G. and colleagues from the Canarian Health System Sequencing Hub were supported by the Instituto de Salud Carlos III (Grants COV20_01333 and COV20_01334), the Spanish Ministry for Science and Innovation (RTC-2017-6471-1; AEI/FEDER, European Union), Fundación DISA (Grants OA18/017 and OA20/024), and Cabildo Insular de Tenerife (Grants CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). T.H.M. was supported by grants from the Novo Nordisk Foundation (Grants NNF20OC0064890 and NNF21OC0067157). C.M.B. is supported by a Michael Smith Foundation for Health Research Health Professional-Investigator Award. P.Q.H. and L. Hammarström were funded by the European Union’s Horizon 2020 research and innovation program (Antibody Therapy Against Coronavirus consortium, Grant 101003650). Work at Y.-L.L.’s laboratory in the University of Hong Kong (HKU) was supported by the Society for the Relief of Disabled Children. MBBS/PhD study of D.L. in HKU was supported by the Croucher Foundation. J.L.F. was supported in part by the Evaluation-Orientation de la Coopération Scientifique (ECOS) Nord - Coopération Scientifique France-Colombie (ECOS-Nord/Columbian Administrative department of Science, Technology and Innovation [COLCIENCIAS]/Colombian Ministry of National Education [MEN]/Colombian Institute of Educational Credit and Technical Studies Abroad [ICETEX, Grant 806-2018] and Colciencias Contract 713-2016 [Code 111574455633]). A. Klocperk was, in part, supported by Grants NU20-05-00282 and NV18-05-00162 issued by the Czech Health Research Council and Ministry of Health, Czech Republic. L.P. was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (Grant COVID-2020-12371617). I.M. is a Senior Clinical Investigator at the Research Foundation–Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies (PID); by the Katholieke Universiteit Leuven C1 Grant C16/18/007; by a Flanders Institute for Biotechnology-Grand Challenges - PID grant; by the FWO Grants G0C8517N, G0B5120N, and G0E8420N; and by the Jeffrey Modell Foundation. I.M. has received funding under the European Union’s Horizon 2020 research and innovation program (Grant Agreement 948959). E.A. received funding from the Hellenic Foundation for Research and Innovation (Grant INTERFLU 1574). M. Vidigal received funding from the São Paulo Research Foundation (Grant 2020/09702-1) and JBS SA (Grant 69004). The NH-COVAIR study group consortium was supported by a grant from the Meath Foundation.

Footnotes

Reviewers: M. Carrington, Frederick National Laboratory for Cancer Research; A. Flahault, Universite de Geneve Institut de Sante Globale; and A.T., Scripps Center for Integrative Medicine.

The authors declare a competing interest. J.-L.C. is an inventor on patent application PCT/US2021/042741, filed 22 July 2021, submitted by The Rockefeller University, which covers diagnosis of, susceptibility to, and treatment of viral disease and viral vaccines, including COVID-19 and vaccine-associated diseases. M.C.N. is an inventor on patent application PCT/US2021/070472 submitted by The Rockefeller University that covers neutralizing anti-SARS-CoV-2 antibodies and methods of the use thereof. M.C.N. reports being on the Scientific Advisory Board of Celldex and Frontier Biotechnologies. R.P.L. reports being a non-executive director of Roche.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2200413119/-/DCSupplemental.

Contributor Information

Collaborators: Peng Zhang, Yoann Seeleuthner, Estelle Talouarn, Astrid Marchal, Daniela Matuozzo, Aliénor de la Chapelle, Jie Chen, Maya Chrabieh, Dana Liu, Yelena Nemirowskaya, Inés Marín Cruz, Marie Materna, Sophie Pelet, Chloé Thibault, Zhiyong Liu, Jorge Abad, Giulia Accordino, Cristian Achille, Sergio Aguilera-Albesa, Aina Aguiló-Cucurull, Alessandro Aiuti, Esra Akyüz Özkan, Ilad Alavi Darazam, Jonathan Antonio Roblero Albisures, Juan C. Aldave, Miquel Alfonso Ramos, Taj Ali Khan, Anna Aliberti, Seyed Alireza Nadji, Gulsum Alkan, Suzan A. AlKhater, Jerome Allardet-Servent, Luis M. Allende, Rebeca Alonso-Arias, Mohammed S. Alshahrani, Laia Alsina, Marie-Alexandra Alyanakian, Blanca Amador Borrero, Zahir Amoura, Arnau Antolí, Romain Arrestier, Mélodie Aubart, Teresa Auguet, Iryna Avramenko, Gökhan Aytekin, Axelle Azot, Seiamak Bahram, Fanny Bajolle, Fausto Baldanti, Aurélie Baldolli, Maite Ballester, Hagit Baris Feldman, Benoit Barrou, Federica Barzaghi, Sabrina Basso, Gulsum Iclal Bayhan, Alexandre Belot, Liliana Bezrodnik, Agurtzane Bilbao, Geraldine Blanchard-Rohner, Ignacio Blanco, Adeline Blandinières, Daniel Blázquez-Gamero, Alexandre Bleibtreu, Marketa Bloomfield, Mireia Bolivar-Prados, Anastasiia Bondarenko, Alessandro Borghesi, Raphael Borie, Elisabeth Botdhlo-Nevers, Ahmed A. Bousfiha, Aurore Bousquet, David Boutolleau, Claire Bouvattier, Oksana Boyarchuk, Juliette Bravais, M. Luisa Briones, Marie-Eve Brunner, Raffaele Bruno, Maria Rita P. Bueno, Huda Bukhari, Jacinta Bustamante, Juan José Cáceres Agra, Ruggero Capra, Raphael Carapito, Maria Carrabba, Giorgio Casari, Carlos Casasnovas, Marion Caseris, Irene Cassaniti, Martin Castelle, Francesco Castelli, Martín Castillo de Vera, Mateus V. Castro, Emilie Catherinot, Jale Bengi Celik, Alessandro Ceschi, Martin Chalumeau, Bruno Charbit, Matthew P. Cheng, Pere Clavé, Bonaventura Clotet, Anna Codina, Yves Cohen, Roger Colobran, Cloé Comarmond, Alain Combes, Patrizia Comoli, Angelo G. Corsico, Taner Coşkuner, Aleksandar Cvetkovski, Cyril Cyrus, David Dalmau, François Danion, David Ross Darley, Vincent Das, Nicolas Dauby, Stéphane Dauger, Paul De Munter, Loic de Pontual, Amin Dehban, Geoffroy Delplancq, Alexandre Demoule, Isabelle Desguerre, Antonio Di Sabatino, Jean-Luc Diehl, Stephanie Dobbelaere, Elena Domínguez-Garrido, Clément Dubost, Olov Ekwall, Şefika Elmas Bozdemir, Marwa H. Elnagdy, Melike Emiroglu, Akifumi Endo, Emine Hafize Erdeniz, Selma Erol Aytekin, Maria Pilar Etxart Lasa, Romain Euvrard, Giovanna Fabio, Laurence Faivre, Antonin Falck, Muriel Fartoukh, Morgane Faure, Miguel Fernandez Arquero, Ricard Ferrer, Jose Ferreres, Carlos Flores, Bruno Francois, Victoria Fumadó, Kitty S. C. Fung, Francesca Fusco, Alenka Gagro, Blanca Garcia Solis, Pascale Gaussem, Zeynep Gayretli, Juana Gil-Herrera, Laurent Gilardin, Audrey Giraud Gatineau, Mònica Girona-Alarcón, Karen Alejandra Cifuentes Godínez, Jean-Christophe Goffard, Nacho Gonzales, Luis I. Gonzalez-Granado, Rafaela González-Montelongo, Antoine Guerder, Belgin Gülhan, Victor Daniel Gumucio, Leif Gunnar Hanitsch, Jan Gunst, Marta Gut, Jérôme Hadjadj, Filomeen Haerynck, Rabih Halwani, Lennart Hammarström, Selda HANCERLI, Tetyana Hariyan, Nevin Hatipoglu, Deniz Heppekcan, Elisa Hernandez-Brito, Po-ki Ho, María Soledad Holanda-Peña, Juan P. Horcajada, Sami Hraiech, Linda Humbert, Ivan F. N. Hung, Alejandro D. Iglesias, Antonio Íñigo-Campos, Matthieu Jamme, María Jesús Arranz, Marie-Thérèse Jimeno, Iolanda Jordan, Saliha Kanık-Yüksek, Yalcin Burak Kara, Aydın Karahan, Adem Karbuz, Kadriye Kart Yasar, Ozgur Kasapcopur, Kenichi Kashimada, Sevgi Keles, Yasemin Kendir Demirkol, Yasutoshi Kido, Can Kizil, Ahmet Osman Kılıç, Adam Klocperk, Maria Daganou, Evangelia Koukaki, Antonia Koutsoukou, Vasiliki Rapti, Konstantinos Syrigos, Zbigniew J. Król, Hatem Ksouri, Paul Kuentz, Arthur M. C. Kwan, Yat Wah M. Kwan, Janette S. Y. Kwok, Jean-Christophe Lagier, David S. Y. Lam, Francesca Conti, Andrea Pession, Vicky Lampropoulou, Fanny Lanternier, Yu-Lung Lau, Fleur Le Bourgeois, Yee-Sin Leo, Rafael Leon Lopez, Daniel Leung, Michael Levin, Michael Levy, Romain Lévy, Zhi Li, Daniele Lilleri, Edson Jose Adrian Bolanos Lima, Agnes Linglart, Eduardo López-Collazo, José M. Lorenzo-Salazar, Céline Louapre, Catherine Lubetzki, Kwok-Cheung Lung, Charles-Edouard Luyt, David C. Lye, Cinthia Magnone, Davood Mansouri, Enrico Marchioni, Carola Marioli, Majid Marjani, Laura Marques, Jesus Marquez Pereira, Andrea Martín-Nalda, David Martínez Pueyo, Javier Martinez-Picado, Iciar Marzana, Carmen Mata-Martínez, Alexis Mathian, Larissa RB Matos, Gail V. Matthews, Julien Mayaux, Raquel McLaughlin-Garcia, Philippe Meersseman, Jean-Louis Mège, Armand Mekontso-Dessap, Isabelle Melki, Federica Meloni, Jean-François Meritet, Paolo Merlani, Özge Metin Akcan, Isabelle Meyts, Mehdi Mezidi, Isabelle Migeotte, Maude Millereux, Matthieu Million, Tristan Mirault, Clotilde Mircher, Mehdi Mirsaeidi, Yoko Mizoguchi, Bhavi P. Modi, Francesco Mojoli, Elsa Moncomble, Abián Montesdeoca Melián, Antonio Morales Martinez, Francisco Morandeira, Pierre-Emmanuel Morange, Clémence Mordacq, Guillaume Morelle, Stéphane J. Mouly, Adrián Muñoz-Barrera, Cyril Nafati, Shintaro Nagashima, Yu Nakagama, Bénédicte Neven, João Farela Neves, Lisa F. P. Ng, Yuk-Yung Ng, Hubert Nielly, Yeray Novoa Medina, Esmeralda Nuñez Cuadros, J. Gonzalo Ocejo-Vinyals, Keisuke Okamoto, Mehdi Oualha, Amani Ouedrani, Tayfun Özçelik, Aslinur Ozkaya-Parlakay, Michele Pagani, Qiang Pan-Hammarström, Maria Papadaki, Christophe Parizot, Philippe Parola, Tiffany Pascreau, Stéphane Paul, Estela Paz-Artal, Sigifredo Pedraza-Sánchez, José Luis Gálvez-Romero, Nancy Carolina González Pellecer, Silvia Pellegrini, Rebeca Pérez de Diego, Xosé Luis Pérez-Fernández, Aurélien Philippe, Quentin Philippot, Adrien Picod, Marc Pineton de Chambrun, Antonio Piralla, Laura Planas-Serra, Dominique Ploin, Julien Poissy, Géraldine Poncelet, Garyphallia Poulakou, Marie S. Pouletty, Persia Pourshahnazari, Jia Li Qiu-Chen, Paul Quentric, Thomas Rambaud, Didier Raoult, Violette Raoult, Anne-Sophie Rebillat, Claire Redin, Léa Resmini, Pilar Ricart, Jean-Christophe Richard, Raúl Rigo-Bonnin, Nadia rivet, Jacques G. Rivière, Gemma Rocamora-Blanch, Mathieu P. Rodero, Carlos Rodrigo, Luis Antonio Rodriguez, Carlos Rodriguez-Gallego, Agustí Rodriguez-Palmero, Carolina Soledad Romero, Anya Rothenbuhler, Damien Roux, Nikoletta Rovina, Flore Rozenberg, Yvon Ruch, Montse Ruiz, Maria Yolanda Ruiz del Prado, Juan Carlos Ruiz-Rodriguez, Joan Sabater-Riera, Kai Saks, Maria Salagianni, Oliver Sanchez, Adrián Sánchez-Montalvá, Silvia Sánchez-Ramón, Laire Schidlowski, Agatha Schluter, Julien Schmidt, Matthieu Schmidt, Catharina Schuetz, Cyril E. Schweitzer, Francesco Scolari, Anna Sediva, Luis Seijo, Analia Gisela Seminario, Damien Sene, Piseth Seng, Sevtap Senoglu, Mikko Seppänen, Alex Serra Llovich, Mohammad Shahrooei, Anna Shcherbina, Virginie Siguret, Eleni Siouti, David M. Smadja, Nikaia Smith, Ali Sobh, Xavier Solanich, Jordi Solé-Violán, Catherine Soler, Pere Soler-Palacín, Betül Sözeri, Giulia Maria Stella, Yuriy Stepanovskiy, Annabelle Stoclin, Fabio Taccone, Yacine Tandjaoui-Lambiotte, Jean-Luc Taupin, Simon J. Tavernier, Loreto Vidaur, Benjamin Terrier, Guillaume Thiery, Christian Thorball, Karolina Thorn, Caroline Thumerelle, Imran Tipu, Martin Tolstrup, Gabriele Tomasoni, Julie Toubiana, Josep Trenado Alvarez, Sophie Trouillet-Assant, Jesús Troya, Owen T. Y. Tsang, Liina Tserel, Eugene Y. K. Tso, Alessandra Tucci, Şadiye Kübra Tüter Öz, Matilde Valeria Ursini, Takanori Utsumi, Yurdagul Uzunhan, Pierre Vabres, Juan Valencia-Ramos, Ana Maria Van Den Rym, Isabelle Vandernoot, Valentina Velez-Santamaria, Silvia Patricia Zuniga Veliz, Mateus C. Vidigal, Sébastien Viel, Cédric Villain, Marie E. Vilaire-Meunier, Judit Villar-García, Audrey Vincent, Guillaume Vogt, Guillaume Voiriot, Alla Volokha, Fanny Vuotto, Els Wauters, Joost Wauters, Alan K. L. Wu, Tak-Chiu Wu, Aysun Yahşi, Osman Yesilbas, Mehmet Yildiz, Barnaby E. Young, Ufuk Yükselmiş, Mayana Zatz, Stefano Ghirardello, Valentina Zuccaro, Ana de Andrés, Jens Van Praet, Bart N. Lambrecht, Eva Van Braeckel, Cédric Bosteels, Levi Hoste, Eric Hoste, Fré Bauters, Jozefien De Clercq, Cathérine Heijmans, Hans Slabbynck, Leslie Naesens, Benoit Florkin, Cécile Boulanger, Dimitri Vanderlinden, Giuseppe Foti, Giacomo Bellani, Giuseppe Citerio, Ernesto Contro, Alberto Pesci, Maria Grazia Valsecchi, Marina Cazzaniga, Jeffrey J. Danielson, Kerry Dobbs, Anuj Kashyap, Li Ding, Clifton L. Dalgard, Alessandra Sottini, Virginia Quaresima, Eugenia Quiros-Roldan, Camillo Rossi, Laura Rachele Bettini, Mariella D’Angio, Ilaria Beretta, Daniela Montagna, Amelia Licari, Gian Luigi Marseglia, Isabella Batten, Conor Reddy, Matt McElheron, Claire Noonan, Emma Connolly, Aoife Fallon, Merete Storgaard, Sofie Jørgensen, Martin Tolstrup, Christian Erikstrup, Ole Birger Pedersen, Erik Sørensen, Susan Mikkelsen, Khoa Manh Dinh, Margit Anita Hørup Larsen, Isabella Worlewenut Paulsen, Jakob Hjorth Von Stemann, Morten Bagge Hansen, Sisse Rye Ostrowski, Liam Townsend, Cliona Ni Cheallaigh, Colm Bergin, Ignacio Martin-Loeches, Jean Dunne, Niall Conlon, Nollaig Bourke, Cliona O’Farrelly, Laurent Abel, Clotilde Allavena, Claire Andrejak, François Angoulvant, Cecile Azoulay, Delphine Bachelet, Marie Bartoli, Romain Basmaci, Sylvie Behillill, Marine Beluze, Nicolas Benech, Dehbia Benkerrou, Krishna Bhavsar, Laurent Bitker, Lila Bouadma, Maude Bouscambert-Duchamp, Pauline Caraux Paz, Minerva Cervantes-Gonzalez, Anissa Chair, Catherine Chirouze, Alexandra Coelho, Hugues Cordel, Camille Couffignal, Sandrine Couffin-Cadiergues, Eric d’Ortenzio, Etienne De Montmollin, Alexa Debard, Marie-Pierre Debray, Dominique Deplanque, Diane Descamps, Mathilde Desvallée, Alpha Diallo, Jean-Luc Diehl, Alphonsine Diouf, Céline Dorival, François Dubos, Xavier Duval, Philippine Eloy, Vincent Enouf, Olivier Epaulard, Hélène Esperou, Marina Esposito-Farase, Manuel Etienne, Denis Garot, Nathalie Gault, Alexandre Gaymard, Jade Ghosn, Tristan Gigante, Morgane Gilg, François Goehringer, Jérémie Guedj, Alexandre Hoctin, Isabelle Hoffmann, Ikram Houas, Jean-Sébastien Hulot, Salma Jaafoura, Ouifiya Kafif, Florentia Kaguelidou, Sabrina Kali, Younes Kerroumi, Antoine Khalil, Coralie Khan, Antoine Kimmoun, Fabrice Laine, Cédric Laouénan, Samira Laribi, Minh Le, Cyril Le Bris, Sylvie Le Gac, Quentin Le Hingrat, Soizic Le Mestre, Hervé Le Nagard, Adrien Lemaignen, Véronique Lemee, François-Xavier Lescure, Sophie Letrou, Yves Levy, Bruno Lina, Guillaume Lingas, Jean Christophe Lucet, Moïse Machado, Denis Malvy, Marina Mambert, Aldric Manuel, France Mentré, Amina Meziane, Hugo Mouquet, Jimmy Mullaert, Nadège Neant, Duc Nguyen, Marion Noret, Aurélie Papadopoulos, Christelle Paul, Nathan Peiffer-Smadja, Vincent Peigne, Ventzislava Petrov-Sanchez, Gilles Peytavin, Huong Pham, Olivier Picone, Valentine Piquard, Julien Poissy, Oriane Puéchal, Manuel Rosa-Calatrava, Bénédicte Rossignol, Patrick Rossignol, Carine Roy, Marion Schneider, Richa Su, Coralie Tardivon, Marie-Capucine Tellier, François Téoulé, Olivier Terrier, Jean-François Timsit, Christelle Tual, Sarah Tubiana, Sylvie Van Der Werf, Noémie Vanel, Aurélie Veislinger, Benoit Visseaux, Aurélie Wiedemann, Yazdan Yazdanpanah, Jean-Philippe Annereau, Luis Briseño-Roa, Olivier Gribouval, Jean-Philippe Jaïs, Anna Pelet, Laurent Abel, Andres Alcover, Hugues Aschard, Philippe Bousso, Nollaig Bourke, Petter Brodin, Pierre Bruhns, Nadine Cerf-Bensussan, Ana Cumano, Christophe D’Enfert, Ludovic Deriano, Marie-Agnès Dillies, James Di Santo, Françoise Dromer, Gérard Eberl, Jost Enninga, Jacques Fellay, Ivo Gomperts-Boneca, Milena Hasan, Gunilla Karlsson Hedestam, Serge Hercberg, Molly A. Ingersoll, Olivier Lantz, Rose Anne Kenny, Mickaël Ménager, Frédérique Michel, Hugo Mouquet, Cliona O’Farrelly, Etienne Patin, Sandra Pellegrini, Antonio Rausell, Frédéric Rieux-Laucat, Lars Rogge, Magnus Fontes, Anavaj Sakuntabhai, Olivier Schwartz, Benno Schwikowski, Spencer Shorte, Frédéric Tangy, Antoine Toubert, Mathilde Touvier, Marie-Noëlle Ungeheuer, Christophe Zimmer, Matthew L. Albert, Darragh Duffy, Lluis Quintana-Murci, Loubna Alavoine, Sylvie Behillil, Charles Burdet, Charlotte Charpentier, Aline Dechanet, Diane Descamps, Xavier Duval, Jean-Luc Ecobichon, Vincent Enouf, Wahiba Frezouls, Nadhira Houhou, Ouifiya Kafif, Jonathan Lehacaut, Sophie Letrou, Bruno Lina, Jean-Christophe Lucet, Pauline Manchon, Mariama Nouroudine, Valentine Piquard, Caroline Quintin, Michael Thy, Sarah Tubiana, Sylvie van der Werf, Valérie Vignali, Benoit Visseaux, Yazdan Yazdanpanah, Abir Chahine, Nawal Waucquier, Maria-Claire Migaud, Dominique Deplanque, Félix Djossou, Mayka Mergeay-Fabre, Aude Lucarelli, Magalie Demar, Léa Bruneau, Patrick Gérardin, Adrien Maillot, Christine Payet, Bruno Laviolle, Fabrice Laine, Christophe Paris, Mireille Desille-Dugast, Julie Fouchard, Denis Malvy, Duc Nguyen, Thierry Pistone, Pauline Perreau, Valérie Gissot, Carole Le Goas, Samatha Montagne, Lucie Richard, Catherine Chirouze, Kévin Bouiller, Maxime Desmarets, Alexandre Meunier, Marilou Bourgeon, Benjamin Lefèvre, Hélène Jeulin, Karine Legrand, Sandra Lomazzi, Bernard Tardy, Amandine Gagneux-Brunon, Frédérique Bertholon, Elisabeth Botelho-Nevers, Christelle Kouakam, Nicolas Leturque, Layidé Roufai, Karine Amat, Sandrine Couffin-Cadiergues, Hélène Espérou, Samia Hendou, Michiel van Agtmael, Anne Geke Algera, Brent Appelman, Frank van Baarle, Diane Bax, Martijn Beudel, Harm Jan Bogaard, Marije Bomers, Peter Bonta, Lieuwe Bos, Michela Botta, Justin de Brabander, Godelieve de Bree, Sanne de Bruin, David T. P. Buis, Marianna Bugiani, Esther Bulle, Osoul Chouchane, Alex Cloherty, Mirjam Dijkstra, Dave A. Dongelmans, Romein W. G. Dujardin, Paul Elbers, Lucas Fleuren, Suzanne Geerlings, Theo Geijtenbeek, Armand Girbes, Bram Goorhuis, Martin P. Grobusch, Florianne Hafkamp, Laura Hagens, Jorg Hamann, Vanessa Harris, Robert Hemke, Sabine M. Hermans, Leo Heunks, Markus Hollmann, Janneke Horn, Joppe W. Hovius, Menno D. de Jong, Rutger Koning, Endry H. T. Lim, Niels van Mourik, Jeaninne Nellen, Esther J. Nossent, Frederique Paulus, Edgar Peters, Dan A. I. Pina-Fuentes, Tom van der Poll, Bennedikt Preckel, Jan M. Prins, Jorinde Raasveld, Tom Reijnders, Maurits C. F. J. de Rotte, Michiel Schinkel, Marcus J. Schultz, Femke A. P. Schrauwen, Alex Schuurman, Jaap Schuurmans, Kim Sigaloff, Marleen A. Slim, Patrick Smeele, Marry Smit, Cornelis S. Stijnis, Willemke Stilma, Charlotte Teunissen, Patrick Thoral, Anissa M. Tsonas, Pieter R. Tuinman, Marc van der Valk, Denise Veelo, Carolien Volleman, Heder de Vries, Lonneke A. Vught, Michèle van Vugt, Dorien Wouters, A. H. (Koos) Zwinderman, Matthijs C. Brouwer, W. Joost Wiersinga, Alexander P. J. Vlaar, Diederik van de Beek, Laurent Abel, Alessandro Aiuti, Saleh Al-Muhsen, Fahd Al-Mulla, Mark S. Anderson, Evangelos Andreakos, Andrés A. Arias, Hagit Baris Feldman, Alexandre Belot, Catherine M. Biggs, Dusan Bogunovic, Alexandre Bolze, Anastasiia Bondarenko, Ahmed A. Bousfiha, Petter Brodin, Yenan Bryceson, Carlos D. Bustamante, Manish J. Butte, Giorgio Casari, Samya Chakravorty, John Christodoulou, Antonio Condino-Neto, Stefan N. Constantinescu, Megan A. Cooper, Clifton L. Dalgard, Murkesh Desai, Beth A. Drolet, Jamila El Baghdadi, Sara Espinosa-Padilla, Jacques Fellay, Carlos Flores, José Luis Franco, Antoine Froidure, Peter K. Gregersen, Filomeen Haerynck, David Hagin, Rabih Halwani, Lennart Hammarström, James R. Heath, Sarah E. Henrickson, Elena W. Y. Hsieh, Eystein S. Husebye, Kohsuke Imai, Yuval Itan, Erich D. Jarvis, Timokratis Karamitros, Kai Kisand, Cheng-Lung Ku, Yu-Lung Lau, Yun Ling, Carrie L. Lucas, Tom Maniatis, Davood Mansouri, László Maródi, Isabelle Meyts, Joshua D. Milner, Kristina Mironska, Trine H. Mogensen, Tomohiro Morio, Lisa F. P. Ng, Luigi D. Notarangelo, Antonio Novelli, Giuseppe Novelli, Cliona O’Farrelly, Satoshi Okada, Tayfun Ozcelik, Qiang Pan-Hammarström, Rebeca Perez de Diego, Anna M. Planas, Jordi Perez-Tur, Lisa M. Arkin, Takaki Asano, Roger Colobran Oriol, Carolina Prando, Aurora Pujol, Lluis Quintana-Murci, Laurent Renia, Igor Resnick, Carlos Rodríguez-Gallego, Vanessa Sancho-Shimizu, Anna Sediva, Mikko R.J. Seppänen, Mohammed Shahrooei, Anna Shcherbina, Ondrej Slaby, Andrew L. Snow, Pere Soler-Palacín, András N. Spaan, Ivan Tancevski, Stuart G. Tangye, Ahmad Abou Tayoun, Sathishkumar Ramaswamy, Stuart E. Turvey, K. M. Furkan Uddin, Mohammed J. Uddin, Diederik van de Beek, Donald C. Vinh, Horst von Bernuth, Mayana Zatz, Pawel Zawadzki, Bodo Grimbacher, Keisuke Okamoto, Jean W. Pape, David S. Perlin, Graziano Pesole, Joost Wauters, Helen C. Su, Jean-Laurent Casanova, Paula Andrea Gaviria García, Gustavo Andrés Salguero López, Adriana Rojas-Villaraga, Verónica Posada Vélez, Lina Marcela Acevedo Landinez, Luisa Paola Duarte Correales, Oscar Gómez, Jeser Santiago Grass Guaqueta, Cristian Alejandro Ricaurte Pérez, Jorge Carrillo, José Alejandro Daza Vergara, Sandra Landinez, Rubén D. Mantilla, Jairo David Torres Yepes, Oscar Andrés Briceño Ricaurte, Carlos E. Pérez-Díaz, Yady Nataly Mateus, Laura Mancera Navarro, Yhojan Rodríguez, Yeny Acosta-Ampudia, Diana M. Monsalve, Manuel Rojas, Rachel Nadif, Marcel Goldberg, Anna Ozguler, Joseph Henny, Sylvie Lemonnier, Mireille Coeuret-Pellicer, Stéphane Le Got, Marie Zins, Christophe Tzourio, Stéphanie Debette, Carole Dufouil, Aïcha Soumaré, Morgane Lachaize, Nathalie Fievet, Amandine Flaig, Fernando Martin, Brigitte Bonneaudeau, Fabrice Cognasse, Dorothée Cannet, Pierre Gallian, Michel Jeanne, Pascal Morel, Magali Perroquin, Pascale Richard, Pierre Tiberghien, and Hind Hamzeh-Cognasse

Data Availability

All the data are available in the manuscript or in the supporting information. Plasma, cells, and genomic DNA are available from J.-L.C. under a material transfer agreement (MTA) with The Rockefeller University or the Imagine Institute. Huh-7.5 cells are available on request from C.M.R. under an MTA with The Rockefeller University and Apath LLC. The materials and reagents used are almost exclusively commercially available and nonproprietary. Materials derived from human samples may be made available on request, subject to any underlying restrictions concerning such samples.

References

1.Hu B., Guo H., Zhou P., Shi Z. L., Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Telenti A., et al. , After the pandemic: Perspectives on the future trajectory of COVID-19. Nature 596, 495–504 (2021). [DOI] [PubMed] [Google Scholar]
3.Zhang Q., Bastard P., Cobat A., Casanova J. L.; COVID Human Genetic Effort, Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature 603, 587–598 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Pei S., Yamana T. K., Kandula S., Galanti M., Shaman J., Burden and characteristics of COVID-19 in the United States during 2020. Nature 598, 338–341 (2021). [DOI] [PubMed] [Google Scholar]
5.Zhang Q., et al. ; COVID Human Genetic Effort, Life-threatening COVID-19: Defective interferons unleash excessive inflammation. Med (N Y) 1, 14–20 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
6.O’Driscoll M., et al. , Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590, 140–145 (2021). [DOI] [PubMed] [Google Scholar]
7.Levin A. T., et al. , Assessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol. 35, 1123–1138 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Brodin P., Immune determinants of COVID-19 disease presentation and severity. Nat. Med. 27, 28–33 (2021). [DOI] [PubMed] [Google Scholar]
9.Duncan C. J. A., Randall R. E., Hambleton S., Genetic lesions of Type I interferon signalling in human antiviral immunity. Trends Genet. 37, 46–58 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Casanova J. L., Su H. C.; COVID Human Genetic Effort, A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell 181, 1194–1199 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Bastard P., et al. ; HGID Lab; COVID Clinicians; COVID-STORM Clinicians; NIAID Immune Response to COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; St. James’s Hospital; SARS CoV2 Interest group; French COVID Cohort Study Group; Imagine COVID-Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19; Biobank Investigators; COVID Human Genetic Effort; CONSTANCES cohort; 3C-Dijon Study; Cerba Health-Care; Etablissement du Sang study group, Autoantibodies neutralizing type I IFNs are present in ∼4% of uninfected individuals over 70 years old and account for ∼20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Bastard P., et al. ; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort, Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Asano T., et al. ; COVID Human Genetic Effort; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group; CoV-Contact Cohort; Amsterdam UMC Covid-; Biobank; NIAID-USUHS COVID Study Group, X-linked recessive TLR7 deficiency in ∼1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol. 6, eabl4348 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Zhang Q., et al. ; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort; NIAID-USUHS/TAGC COVID Immunity Group, Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Khanmohammadi S., Rezaei N., Khazaei M., Shirkani A., A case of autosomal recessive interferon alpha/beta receptor alpha chain (IFNAR1) deficiency with severe COVID-19. J. Clin. Immunol. 42, 19–24 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Abolhassani H., et al. , Inherited IFNAR1 deficiency in a child with both critical COVID-19 pneumonia and multisystem inflammatory syndrome. J. Clin. Immunol., 10.1007/s10875-022-01215-7 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Schmidt A., et al. , TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. NPJ Genom. Med. 6, 55 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Abolhassani H., et al. , X-linked TLR7 deficiency underlies critical COVID-19 pneumonia in a male patient with ataxia-telangiectasia. J. Clin. Immunol. 42, 1–9 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Casanova J. L., Abel L., Mechanisms of viral inflammation and disease in humans. Science 374, 1080–1086 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Goncalves D., et al. , Antibodies against type I interferon: Detection and association with severe clinical outcome in COVID-19 patients. Clin. Transl. Immunology 10, e1327 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Shaw E. R., et al. , Temporal dynamics of anti-type 1 interferon autoantibodies in COVID-19 patients. Clin. Infect. Dis., 10.1093/cid/ciab1002 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Savvateeva E., et al. , Microarray-based detection of antibodies against SARS-CoV-2 proteins, common respiratory viruses and Type I interferons. Viruses 13, 2553 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Koning R., Bastard P., Casanova J. L., Brouwer M. C., van de Beek D.; with the Amsterdam U.M.C. COVID-19 Biobank Investigators, Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 47, 704–706 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Troya J., et al. , Neutralizing autoantibodies to Type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J. Clin. Immunol. 41, 914–922 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
25.van der Wijst M. G. P., et al. ; UCSF COMET consortium, Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 13, eabh2624 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Vazquez S. E., et al. , Neutralizing autoantibodies to Type I interferons in COVID-19 convalescent donor plasma. J. Clin. Immunol. 41, 1169–1171 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
27.Wang E. Y., et al. ; Yale IMPACT Team, Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283–288 (2021). [DOI] [PubMed] [Google Scholar]
28.Abers M. S., et al. , Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol. Cell Biol. 99, 917–921 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Chauvineau-Grenier A., et al. , Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital. J. Clin. Immunol., https://doi.org/10.1007/s10875-021-01203-3 (2022). [DOI] [PMC free article] [PubMed]
30.Solanich X., et al. , Pre-existing autoantibodies neutralizing high concentrations of type I interferons in almost 10% of COVID-19 patients admitted to intensive care in Barcelona. J. Clin. Immunol. 41, 1733–1744 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Raadsen M. P., et al. , Interferon-α2 auto-antibodies in convalescent plasma therapy for COVID-19. J. Clin. Immunol. 42, 232–239 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
32.Chang S. E., et al. , New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 12, 5417 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Ziegler C. G. K., et al. , Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell 184, 4713–4733.e22 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Acosta-Ampudia Y., et al. ; CP-COVID-19 group, COVID-19 convalescent plasma composition and immunological effects in severe patients. J. Autoimmun. 118, 102598 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Carapito R., et al. , Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Sci. Transl. Med. 14, eabj7521 (2022). [DOI] [PubMed] [Google Scholar]
36.Bastard P., et al. , Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J. Exp. Med. 218, e20210554 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
37.van der Wijst M. G. P., et al. , Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 13, eabh2624 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
38.Galani I. E., et al. , Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 22, 32–40 (2021). [DOI] [PubMed] [Google Scholar]
39.Sposito B., et al. , The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell 184, 4953–4968.e16 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
40.Lopez J., et al. , Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J. Exp. Med. 218, e20211211 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Blanco-Melo D., et al. , Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045.e9 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Israelow B., et al. , Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J. Exp. Med. 217, e20201241 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Döffinger R., et al. , Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. 38, e10–e14 (2004). [DOI] [PubMed] [Google Scholar]
44.Höflich C., et al. , Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103, 673–675 (2004). [DOI] [PubMed] [Google Scholar]
45.Kampmann B., et al. , Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J. Clin. Invest. 115, 2480–2488 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
46.Puel A., et al. , Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J. Immunol. 180, 647–654 (2008). [DOI] [PubMed] [Google Scholar]
47.Puel A., et al. , Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207, 291–297 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
48.Ku C. L., Chi C. Y., von Bernuth H., Doffinger R., Autoantibodies against cytokines: Phenocopies of primary immunodeficiencies? Hum. Genet. 139, 783–794 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Kisand K., et al. , Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207, 299–308 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
50.Rosen L. B., et al. , Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis. Clin. Infect. Dis. 60, 1017–1025 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
51.Casanova J. L., Abel L., Lethal infectious diseases as inborn errors of immunity: Toward a synthesis of the germ and genetic theories. Annu. Rev. Pathol. 16, 23–50 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
52.Bastard P., Why do people die from COVID-19? Science 375, 829–830 (2022). [DOI] [PubMed] [Google Scholar]
53.Bastard P., Zhang Q., Zhang S. Y., Jouanguy E., Casanova J. L., Type I interferons and SARS-CoV-2: From cells to organisms. Curr. Opin. Immunol. 74, 172–182 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
54.Morabia A., Ten Have T., Landis J. R., Empirical evaluation of the influence of control selection schemes on relative risk estimation: The Welsh nickel workers study. Occup. Environ. Med. 52, 489–493 (1995). [DOI] [PMC free article] [PubMed] [Google Scholar]
55.Bartleson J. M., et al. , SARS-CoV-2, COVID-19 and the ageing immune system. Nat Aging 1, 769–782 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
56.Splunter M. V., et al. , Plasmacytoid dendritic cell and myeloid dendritic cell function in ageing: A comparison between elderly and young adult women. PLoS One 14, e0225825 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Schultze J. L., Aschenbrenner A. C., COVID-19 and the human innate immune system. Cell 184, 1671–1692 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
58.Stark G. R., Darnell J. E. Jr., The JAK-STAT pathway at twenty. Immunity 36, 503–514 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
59.Pierce C. A., et al. , Natural mucosal barriers and COVID-19 in children. JCI Insight 6, 148694 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
60.Manry J., et al. , Evolutionary genetic dissection of human interferons. J. Exp. Med. 208, 2747–2759 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
61.Ng C. T., et al. , Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe 17, 653–661 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
62.Vinh D. C., et al. ; COVID Human Genetic Effort, Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β. J. Clin. Immunol. 41, 1425–1442 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
63.Weinreich D. M., et al. ; Trial Investigators, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384, 238–251 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
64.Bastard P., et al. , Interferon-β therapy in a patient with incontinentia pigmenti and autoantibodies against Type I IFNs infected with SARS-CoV-2. J. Clin. Immunol. 41, 931–933 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
65.Monk P. D., et al. ; Inhaled Interferon Beta COVID-19 Study Group, Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, 196–206 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
66.Bastard P., et al. , Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J. Exp. Med. 218, e20202486 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
67.von Cube M., Timsit J. F., Schumacher M., Motschall E., Schumacher M., Quantification and interpretation of attributable mortality in core clinical infectious disease journals. Lancet Infect. Dis. 20, e299–e306 (2020). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary File

pnas.2200413119.sapp.pdf^{(1,008.8KB, pdf)}

Data Availability Statement

[r1] 1.Hu B., Guo H., Zhou P., Shi Z. L., Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r2] 2.Telenti A., et al. , After the pandemic: Perspectives on the future trajectory of COVID-19. Nature 596, 495–504 (2021). [DOI] [PubMed] [Google Scholar]

[r3] 3.Zhang Q., Bastard P., Cobat A., Casanova J. L.; COVID Human Genetic Effort, Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature 603, 587–598 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r4] 4.Pei S., Yamana T. K., Kandula S., Galanti M., Shaman J., Burden and characteristics of COVID-19 in the United States during 2020. Nature 598, 338–341 (2021). [DOI] [PubMed] [Google Scholar]

[r5] 5.Zhang Q., et al. ; COVID Human Genetic Effort, Life-threatening COVID-19: Defective interferons unleash excessive inflammation. Med (N Y) 1, 14–20 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r6] 6.O’Driscoll M., et al. , Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590, 140–145 (2021). [DOI] [PubMed] [Google Scholar]

[r7] 7.Levin A. T., et al. , Assessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol. 35, 1123–1138 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r8] 8.Brodin P., Immune determinants of COVID-19 disease presentation and severity. Nat. Med. 27, 28–33 (2021). [DOI] [PubMed] [Google Scholar]

[r9] 9.Duncan C. J. A., Randall R. E., Hambleton S., Genetic lesions of Type I interferon signalling in human antiviral immunity. Trends Genet. 37, 46–58 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r10] 10.Casanova J. L., Su H. C.; COVID Human Genetic Effort, A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell 181, 1194–1199 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r11] 11.Bastard P., et al. ; HGID Lab; COVID Clinicians; COVID-STORM Clinicians; NIAID Immune Response to COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; St. James’s Hospital; SARS CoV2 Interest group; French COVID Cohort Study Group; Imagine COVID-Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19; Biobank Investigators; COVID Human Genetic Effort; CONSTANCES cohort; 3C-Dijon Study; Cerba Health-Care; Etablissement du Sang study group, Autoantibodies neutralizing type I IFNs are present in ∼4% of uninfected individuals over 70 years old and account for ∼20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r12] 12.Bastard P., et al. ; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort, Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r13] 13.Asano T., et al. ; COVID Human Genetic Effort; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group; CoV-Contact Cohort; Amsterdam UMC Covid-; Biobank; NIAID-USUHS COVID Study Group, X-linked recessive TLR7 deficiency in ∼1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol. 6, eabl4348 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r14] 14.Zhang Q., et al. ; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort; NIAID-USUHS/TAGC COVID Immunity Group, Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r15] 15.Khanmohammadi S., Rezaei N., Khazaei M., Shirkani A., A case of autosomal recessive interferon alpha/beta receptor alpha chain (IFNAR1) deficiency with severe COVID-19. J. Clin. Immunol. 42, 19–24 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r16] 16.Abolhassani H., et al. , Inherited IFNAR1 deficiency in a child with both critical COVID-19 pneumonia and multisystem inflammatory syndrome. J. Clin. Immunol., 10.1007/s10875-022-01215-7 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r17] 17.Schmidt A., et al. , TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. NPJ Genom. Med. 6, 55 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r18] 18.Abolhassani H., et al. , X-linked TLR7 deficiency underlies critical COVID-19 pneumonia in a male patient with ataxia-telangiectasia. J. Clin. Immunol. 42, 1–9 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r19] 19.Casanova J. L., Abel L., Mechanisms of viral inflammation and disease in humans. Science 374, 1080–1086 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r20] 20.Goncalves D., et al. , Antibodies against type I interferon: Detection and association with severe clinical outcome in COVID-19 patients. Clin. Transl. Immunology 10, e1327 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r21] 21.Shaw E. R., et al. , Temporal dynamics of anti-type 1 interferon autoantibodies in COVID-19 patients. Clin. Infect. Dis., 10.1093/cid/ciab1002 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r22] 22.Savvateeva E., et al. , Microarray-based detection of antibodies against SARS-CoV-2 proteins, common respiratory viruses and Type I interferons. Viruses 13, 2553 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r23] 23.Koning R., Bastard P., Casanova J. L., Brouwer M. C., van de Beek D.; with the Amsterdam U.M.C. COVID-19 Biobank Investigators, Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 47, 704–706 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r24] 24.Troya J., et al. , Neutralizing autoantibodies to Type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J. Clin. Immunol. 41, 914–922 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r25] 25.van der Wijst M. G. P., et al. ; UCSF COMET consortium, Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 13, eabh2624 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r26] 26.Vazquez S. E., et al. , Neutralizing autoantibodies to Type I interferons in COVID-19 convalescent donor plasma. J. Clin. Immunol. 41, 1169–1171 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r27] 27.Wang E. Y., et al. ; Yale IMPACT Team, Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283–288 (2021). [DOI] [PubMed] [Google Scholar]

[r28] 28.Abers M. S., et al. , Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol. Cell Biol. 99, 917–921 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r29] 29.Chauvineau-Grenier A., et al. , Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital. J. Clin. Immunol., https://doi.org/10.1007/s10875-021-01203-3 (2022). [DOI] [PMC free article] [PubMed]

[r30] 30.Solanich X., et al. , Pre-existing autoantibodies neutralizing high concentrations of type I interferons in almost 10% of COVID-19 patients admitted to intensive care in Barcelona. J. Clin. Immunol. 41, 1733–1744 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r31] 31.Raadsen M. P., et al. , Interferon-α2 auto-antibodies in convalescent plasma therapy for COVID-19. J. Clin. Immunol. 42, 232–239 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r32] 32.Chang S. E., et al. , New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 12, 5417 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r33] 33.Ziegler C. G. K., et al. , Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell 184, 4713–4733.e22 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r34] 34.Acosta-Ampudia Y., et al. ; CP-COVID-19 group, COVID-19 convalescent plasma composition and immunological effects in severe patients. J. Autoimmun. 118, 102598 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r35] 35.Carapito R., et al. , Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Sci. Transl. Med. 14, eabj7521 (2022). [DOI] [PubMed] [Google Scholar]

[r36] 36.Bastard P., et al. , Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J. Exp. Med. 218, e20210554 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r37] 37.van der Wijst M. G. P., et al. , Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 13, eabh2624 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r38] 38.Galani I. E., et al. , Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 22, 32–40 (2021). [DOI] [PubMed] [Google Scholar]

[r39] 39.Sposito B., et al. , The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell 184, 4953–4968.e16 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r40] 40.Lopez J., et al. , Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J. Exp. Med. 218, e20211211 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r41] 41.Blanco-Melo D., et al. , Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045.e9 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r42] 42.Israelow B., et al. , Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J. Exp. Med. 217, e20201241 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r43] 43.Döffinger R., et al. , Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. 38, e10–e14 (2004). [DOI] [PubMed] [Google Scholar]

[r44] 44.Höflich C., et al. , Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 103, 673–675 (2004). [DOI] [PubMed] [Google Scholar]

[r45] 45.Kampmann B., et al. , Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J. Clin. Invest. 115, 2480–2488 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r46] 46.Puel A., et al. , Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J. Immunol. 180, 647–654 (2008). [DOI] [PubMed] [Google Scholar]

[r47] 47.Puel A., et al. , Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207, 291–297 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r48] 48.Ku C. L., Chi C. Y., von Bernuth H., Doffinger R., Autoantibodies against cytokines: Phenocopies of primary immunodeficiencies? Hum. Genet. 139, 783–794 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r49] 49.Kisand K., et al. , Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207, 299–308 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r50] 50.Rosen L. B., et al. , Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis. Clin. Infect. Dis. 60, 1017–1025 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r51] 51.Casanova J. L., Abel L., Lethal infectious diseases as inborn errors of immunity: Toward a synthesis of the germ and genetic theories. Annu. Rev. Pathol. 16, 23–50 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r52] 52.Bastard P., Why do people die from COVID-19? Science 375, 829–830 (2022). [DOI] [PubMed] [Google Scholar]

[r53] 53.Bastard P., Zhang Q., Zhang S. Y., Jouanguy E., Casanova J. L., Type I interferons and SARS-CoV-2: From cells to organisms. Curr. Opin. Immunol. 74, 172–182 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r54] 54.Morabia A., Ten Have T., Landis J. R., Empirical evaluation of the influence of control selection schemes on relative risk estimation: The Welsh nickel workers study. Occup. Environ. Med. 52, 489–493 (1995). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r55] 55.Bartleson J. M., et al. , SARS-CoV-2, COVID-19 and the ageing immune system. Nat Aging 1, 769–782 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r56] 56.Splunter M. V., et al. , Plasmacytoid dendritic cell and myeloid dendritic cell function in ageing: A comparison between elderly and young adult women. PLoS One 14, e0225825 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r57] 57.Schultze J. L., Aschenbrenner A. C., COVID-19 and the human innate immune system. Cell 184, 1671–1692 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r58] 58.Stark G. R., Darnell J. E. Jr., The JAK-STAT pathway at twenty. Immunity 36, 503–514 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r59] 59.Pierce C. A., et al. , Natural mucosal barriers and COVID-19 in children. JCI Insight 6, 148694 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r60] 60.Manry J., et al. , Evolutionary genetic dissection of human interferons. J. Exp. Med. 208, 2747–2759 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r61] 61.Ng C. T., et al. , Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe 17, 653–661 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r62] 62.Vinh D. C., et al. ; COVID Human Genetic Effort, Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β. J. Clin. Immunol. 41, 1425–1442 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r63] 63.Weinreich D. M., et al. ; Trial Investigators, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384, 238–251 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r64] 64.Bastard P., et al. , Interferon-β therapy in a patient with incontinentia pigmenti and autoantibodies against Type I IFNs infected with SARS-CoV-2. J. Clin. Immunol. 41, 931–933 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r65] 65.Monk P. D., et al. ; Inhaled Interferon Beta COVID-19 Study Group, Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, 196–206 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r66] 66.Bastard P., et al. , Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J. Exp. Med. 218, e20202486 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

[r67] 67.von Cube M., Timsit J. F., Schumacher M., Motschall E., Schumacher M., Quantification and interpretation of attributable mortality in core clinical infectious disease journals. Lancet Infect. Dis. 20, e299–e306 (2020). [DOI] [PubMed] [Google Scholar]

PERMALINK

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

Jérémy Manry

Paul Bastard

Adrian Gervais

Tom Le Voyer

Jérémie Rosain

Quentin Philippot

Eleftherios Michailidis

Hans-Heinrich Hoffmann

Shohei Eto

Marina Garcia-Prat

Lucy Bizien

Alba Parra-Martínez

Rui Yang

Liis Haljasmägi

Mélanie Migaud

Karita Särekannu

Julia Maslovskaja

Nicolas de Prost

Yacine Tandjaoui-Lambiotte

Charles-Edouard Luyt

Blanca Amador-Borrero

Alexandre Gaudet

Julien Poissy

Pascal Morel

Pascale Richard

Fabrice Cognasse

Jesús Troya

Sophie Trouillet-Assant

Alexandre Belot

Kahina Saker

Pierre Garçon

Jacques G Rivière

Jean-Christophe Lagier

Stéphanie Gentile

Lindsey B Rosen

Elana Shaw

Tomohiro Morio

Junko Tanaka

David Dalmau

Pierre-Louis Tharaux

Damien Sene

Alain Stepanian

Bruno Mégarbane

Vasiliki Triantafyllia

Arnaud Fekkar

James R Heath

José Luis Franco

Juan-Manuel Anaya

Jordi Solé-Violán

Luisa Imberti

Andrea Biondi

Paolo Bonfanti

Riccardo Castagnoli

Ottavia M Delmonte

Yu Zhang

Andrew L Snow

Steven M Holland

Catherine M Biggs

Marcela Moncada-Vélez

Andrés Augusto Arias

Lazaro Lorenzo

Soraya Boucherit

Dany Anglicheau

Anna M Planas

Filomeen Haerynck

Sotirija Duvlis

Tayfun Ozcelik

Sevgi Keles

Ahmed A Bousfiha

Jalila El Bakkouri

Carolina Ramirez-Santana

Stéphane Paul

Qiang Pan-Hammarström

Lennart Hammarström

Annabelle Dupont

Alina Kurolap

Christine N Metz

Alessandro Aiuti